CN115590204A - 一种增强哺乳动物抗衰老的组合物 - Google Patents
一种增强哺乳动物抗衰老的组合物 Download PDFInfo
- Publication number
- CN115590204A CN115590204A CN202211363795.3A CN202211363795A CN115590204A CN 115590204 A CN115590204 A CN 115590204A CN 202211363795 A CN202211363795 A CN 202211363795A CN 115590204 A CN115590204 A CN 115590204A
- Authority
- CN
- China
- Prior art keywords
- composition
- vitamin
- component
- protein
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 88
- 230000003712 anti-aging effect Effects 0.000 title claims abstract description 21
- 230000002708 enhancing effect Effects 0.000 title claims abstract description 16
- 241000124008 Mammalia Species 0.000 title claims abstract description 15
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 54
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 54
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 53
- 235000018102 proteins Nutrition 0.000 claims abstract description 52
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 52
- 235000021119 whey protein Nutrition 0.000 claims abstract description 45
- 229940088594 vitamin Drugs 0.000 claims abstract description 39
- 229930003231 vitamin Natural products 0.000 claims abstract description 39
- 235000013343 vitamin Nutrition 0.000 claims abstract description 39
- 239000011782 vitamin Substances 0.000 claims abstract description 39
- 239000005018 casein Substances 0.000 claims abstract description 38
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims abstract description 38
- 235000021240 caseins Nutrition 0.000 claims abstract description 38
- 150000001413 amino acids Chemical class 0.000 claims abstract description 33
- 229920001287 Chondroitin sulfate Polymers 0.000 claims abstract description 20
- 239000006041 probiotic Substances 0.000 claims abstract description 16
- 235000018291 probiotics Nutrition 0.000 claims abstract description 16
- 239000000463 material Substances 0.000 claims abstract description 10
- 239000002366 mineral element Substances 0.000 claims abstract description 7
- FZAQROFXYZPAKI-UHFFFAOYSA-N anthracene-2-sulfonyl chloride Chemical compound C1=CC=CC2=CC3=CC(S(=O)(=O)Cl)=CC=C3C=C21 FZAQROFXYZPAKI-UHFFFAOYSA-N 0.000 claims abstract description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 65
- 239000000843 powder Substances 0.000 claims description 45
- 102000011632 Caseins Human genes 0.000 claims description 37
- 108010076119 Caseins Proteins 0.000 claims description 37
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 34
- 229940024606 amino acid Drugs 0.000 claims description 32
- 235000001014 amino acid Nutrition 0.000 claims description 32
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 30
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 26
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 26
- 229920001353 Dextrin Polymers 0.000 claims description 26
- 239000004375 Dextrin Substances 0.000 claims description 26
- 235000019425 dextrin Nutrition 0.000 claims description 26
- 239000000126 substance Substances 0.000 claims description 26
- 102000014171 Milk Proteins Human genes 0.000 claims description 25
- 108010011756 Milk Proteins Proteins 0.000 claims description 25
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 24
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 24
- 239000011575 calcium Substances 0.000 claims description 24
- 229910052791 calcium Inorganic materials 0.000 claims description 24
- 235000001465 calcium Nutrition 0.000 claims description 24
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 24
- 239000011701 zinc Substances 0.000 claims description 24
- 229910052725 zinc Inorganic materials 0.000 claims description 24
- 235000016804 zinc Nutrition 0.000 claims description 24
- 235000013339 cereals Nutrition 0.000 claims description 23
- 235000021239 milk protein Nutrition 0.000 claims description 23
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 22
- 240000005979 Hordeum vulgare Species 0.000 claims description 21
- 235000007340 Hordeum vulgare Nutrition 0.000 claims description 21
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 20
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 claims description 20
- 150000001720 carbohydrates Chemical class 0.000 claims description 20
- 229910052750 molybdenum Inorganic materials 0.000 claims description 20
- 239000011733 molybdenum Substances 0.000 claims description 20
- 235000010469 Glycine max Nutrition 0.000 claims description 19
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 19
- 235000014633 carbohydrates Nutrition 0.000 claims description 19
- 229940045997 vitamin a Drugs 0.000 claims description 19
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 18
- 240000007594 Oryza sativa Species 0.000 claims description 18
- 235000007164 Oryza sativa Nutrition 0.000 claims description 18
- 235000009566 rice Nutrition 0.000 claims description 18
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 17
- 244000068988 Glycine max Species 0.000 claims description 17
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 17
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 17
- 229960003080 taurine Drugs 0.000 claims description 17
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 16
- 241000519695 Ilex integra Species 0.000 claims description 16
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims description 16
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 16
- 229910052748 manganese Inorganic materials 0.000 claims description 16
- 239000011572 manganese Substances 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 16
- 229910052711 selenium Inorganic materials 0.000 claims description 16
- 239000011669 selenium Substances 0.000 claims description 16
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 15
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 15
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 15
- 235000021329 brown rice Nutrition 0.000 claims description 15
- 239000001913 cellulose Substances 0.000 claims description 15
- 229920002678 cellulose Polymers 0.000 claims description 15
- 235000010980 cellulose Nutrition 0.000 claims description 15
- 229910052804 chromium Inorganic materials 0.000 claims description 15
- 239000011651 chromium Substances 0.000 claims description 15
- 235000019152 folic acid Nutrition 0.000 claims description 15
- 239000011724 folic acid Substances 0.000 claims description 15
- 229960000304 folic acid Drugs 0.000 claims description 15
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 14
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 14
- 229930064664 L-arginine Natural products 0.000 claims description 14
- 235000014852 L-arginine Nutrition 0.000 claims description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 14
- 238000010521 absorption reaction Methods 0.000 claims description 14
- 229910052802 copper Inorganic materials 0.000 claims description 14
- 239000010949 copper Substances 0.000 claims description 14
- 240000003183 Manihot esculenta Species 0.000 claims description 13
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 claims description 13
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 13
- 235000021388 linseed oil Nutrition 0.000 claims description 13
- 239000000944 linseed oil Substances 0.000 claims description 13
- 239000011570 nicotinamide Substances 0.000 claims description 13
- 229960003966 nicotinamide Drugs 0.000 claims description 13
- 235000005152 nicotinamide Nutrition 0.000 claims description 13
- OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 claims description 12
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 12
- 229920000926 Galactomannan Polymers 0.000 claims description 12
- 238000000354 decomposition reaction Methods 0.000 claims description 12
- 239000000787 lecithin Substances 0.000 claims description 12
- 229940067606 lecithin Drugs 0.000 claims description 12
- 235000010445 lecithin Nutrition 0.000 claims description 12
- 150000002632 lipids Chemical class 0.000 claims description 12
- 235000010755 mineral Nutrition 0.000 claims description 12
- 239000011707 mineral Substances 0.000 claims description 12
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims description 12
- PVXPPJIGRGXGCY-TZLCEDOOSA-N 6-O-alpha-D-glucopyranosyl-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)C(O)(CO)O1 PVXPPJIGRGXGCY-TZLCEDOOSA-N 0.000 claims description 11
- 241000186000 Bifidobacterium Species 0.000 claims description 11
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 11
- 235000021323 fish oil Nutrition 0.000 claims description 11
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 11
- 229960000367 inositol Drugs 0.000 claims description 11
- 239000001103 potassium chloride Substances 0.000 claims description 11
- 235000011164 potassium chloride Nutrition 0.000 claims description 11
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims description 10
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 10
- 244000075850 Avena orientalis Species 0.000 claims description 10
- 235000007319 Avena orientalis Nutrition 0.000 claims description 10
- 241000371652 Curvularia clavata Species 0.000 claims description 10
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 10
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 10
- PFRQBZFETXBLTP-UHFFFAOYSA-N Vitamin K2 Natural products C1=CC=C2C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C(=O)C2=C1 PFRQBZFETXBLTP-UHFFFAOYSA-N 0.000 claims description 10
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims description 10
- 229960002079 calcium pantothenate Drugs 0.000 claims description 10
- 235000013351 cheese Nutrition 0.000 claims description 10
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 10
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 10
- DKHGMERMDICWDU-GHDNBGIDSA-N menaquinone-4 Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 DKHGMERMDICWDU-GHDNBGIDSA-N 0.000 claims description 10
- 239000003921 oil Substances 0.000 claims description 10
- 235000019198 oils Nutrition 0.000 claims description 10
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 claims description 10
- 239000011764 pyridoxine hydrochloride Substances 0.000 claims description 10
- 229960004172 pyridoxine hydrochloride Drugs 0.000 claims description 10
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 10
- 235000019155 vitamin A Nutrition 0.000 claims description 10
- 239000011719 vitamin A Substances 0.000 claims description 10
- -1 vitamin A fatty acid ester Chemical class 0.000 claims description 10
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 10
- 235000005282 vitamin D3 Nutrition 0.000 claims description 10
- 239000011647 vitamin D3 Substances 0.000 claims description 10
- 235000019143 vitamin K2 Nutrition 0.000 claims description 10
- 239000011728 vitamin K2 Substances 0.000 claims description 10
- 229940021056 vitamin d3 Drugs 0.000 claims description 10
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 10
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 9
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 9
- 240000008042 Zea mays Species 0.000 claims description 9
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 9
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 9
- 235000020235 chia seed Nutrition 0.000 claims description 9
- 235000005822 corn Nutrition 0.000 claims description 9
- 235000013312 flour Nutrition 0.000 claims description 9
- 239000011630 iodine Substances 0.000 claims description 9
- 229910052740 iodine Inorganic materials 0.000 claims description 9
- 229960002477 riboflavin Drugs 0.000 claims description 9
- 229940007115 shark cartilage extract Drugs 0.000 claims description 9
- 229960000984 tocofersolan Drugs 0.000 claims description 9
- 239000002076 α-tocopherol Substances 0.000 claims description 9
- 235000004835 α-tocopherol Nutrition 0.000 claims description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 8
- 229920002907 Guar gum Polymers 0.000 claims description 8
- 229920002472 Starch Polymers 0.000 claims description 8
- 229930003427 Vitamin E Natural products 0.000 claims description 8
- 229960005070 ascorbic acid Drugs 0.000 claims description 8
- 229960002685 biotin Drugs 0.000 claims description 8
- 235000020958 biotin Nutrition 0.000 claims description 8
- 239000011616 biotin Substances 0.000 claims description 8
- 150000001746 carotenes Chemical class 0.000 claims description 8
- 235000005473 carotenes Nutrition 0.000 claims description 8
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 8
- 235000010417 guar gum Nutrition 0.000 claims description 8
- 239000000665 guar gum Substances 0.000 claims description 8
- 229960002154 guar gum Drugs 0.000 claims description 8
- 239000000049 pigment Substances 0.000 claims description 8
- 235000019192 riboflavin Nutrition 0.000 claims description 8
- 239000002151 riboflavin Substances 0.000 claims description 8
- 235000019698 starch Nutrition 0.000 claims description 8
- 239000008158 vegetable oil Substances 0.000 claims description 8
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 claims description 8
- 229940046009 vitamin E Drugs 0.000 claims description 8
- 235000019165 vitamin E Nutrition 0.000 claims description 8
- 239000011709 vitamin E Substances 0.000 claims description 8
- 235000010493 xanthan gum Nutrition 0.000 claims description 8
- 229920001285 xanthan gum Polymers 0.000 claims description 8
- 239000000230 xanthan gum Substances 0.000 claims description 8
- 229940082509 xanthan gum Drugs 0.000 claims description 8
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 claims description 7
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims description 7
- 235000010323 ascorbic acid Nutrition 0.000 claims description 7
- 239000011668 ascorbic acid Substances 0.000 claims description 7
- 229940041514 candida albicans extract Drugs 0.000 claims description 7
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 7
- 229930195729 fatty acid Natural products 0.000 claims description 7
- 239000000194 fatty acid Substances 0.000 claims description 7
- 239000011706 ferric diphosphate Substances 0.000 claims description 7
- 235000007144 ferric diphosphate Nutrition 0.000 claims description 7
- CADNYOZXMIKYPR-UHFFFAOYSA-B ferric pyrophosphate Chemical compound [Fe+3].[Fe+3].[Fe+3].[Fe+3].[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O CADNYOZXMIKYPR-UHFFFAOYSA-B 0.000 claims description 7
- 229940036404 ferric pyrophosphate Drugs 0.000 claims description 7
- 235000003599 food sweetener Nutrition 0.000 claims description 7
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims description 7
- 230000000529 probiotic effect Effects 0.000 claims description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 7
- 239000000377 silicon dioxide Substances 0.000 claims description 7
- 239000008107 starch Substances 0.000 claims description 7
- 239000003765 sweetening agent Substances 0.000 claims description 7
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 7
- 235000013311 vegetables Nutrition 0.000 claims description 7
- 235000019156 vitamin B Nutrition 0.000 claims description 7
- 239000011720 vitamin B Substances 0.000 claims description 7
- 239000012138 yeast extract Substances 0.000 claims description 7
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 6
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 6
- 239000005913 Maltodextrin Substances 0.000 claims description 6
- 229920002774 Maltodextrin Polymers 0.000 claims description 6
- 235000021307 Triticum Nutrition 0.000 claims description 6
- 229940071162 caseinate Drugs 0.000 claims description 6
- 229940035034 maltodextrin Drugs 0.000 claims description 6
- 229940083466 soybean lecithin Drugs 0.000 claims description 6
- 229960000344 thiamine hydrochloride Drugs 0.000 claims description 6
- 235000019190 thiamine hydrochloride Nutrition 0.000 claims description 6
- 239000011747 thiamine hydrochloride Substances 0.000 claims description 6
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 5
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 5
- 244000062793 Sorghum vulgare Species 0.000 claims description 5
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 5
- 229930003268 Vitamin C Natural products 0.000 claims description 5
- 229930003316 Vitamin D Natural products 0.000 claims description 5
- 239000000796 flavoring agent Substances 0.000 claims description 5
- 235000019634 flavors Nutrition 0.000 claims description 5
- 229910052742 iron Inorganic materials 0.000 claims description 5
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 5
- 235000019713 millet Nutrition 0.000 claims description 5
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims description 5
- 235000020238 sunflower seed Nutrition 0.000 claims description 5
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 5
- 235000019154 vitamin C Nutrition 0.000 claims description 5
- 239000011718 vitamin C Substances 0.000 claims description 5
- 235000019166 vitamin D Nutrition 0.000 claims description 5
- 239000011710 vitamin D Substances 0.000 claims description 5
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 5
- 229940046008 vitamin d Drugs 0.000 claims description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 4
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 claims description 4
- 241000186018 Bifidobacterium adolescentis Species 0.000 claims description 4
- 241001134770 Bifidobacterium animalis Species 0.000 claims description 4
- 241000186016 Bifidobacterium bifidum Species 0.000 claims description 4
- 241000186012 Bifidobacterium breve Species 0.000 claims description 4
- 241001608472 Bifidobacterium longum Species 0.000 claims description 4
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 claims description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 4
- 239000004471 Glycine Substances 0.000 claims description 4
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 4
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 4
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 4
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 4
- 244000199866 Lactobacillus casei Species 0.000 claims description 4
- 235000013958 Lactobacillus casei Nutrition 0.000 claims description 4
- 241000218492 Lactobacillus crispatus Species 0.000 claims description 4
- 241000186673 Lactobacillus delbrueckii Species 0.000 claims description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 4
- 239000004472 Lysine Substances 0.000 claims description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 4
- 235000006089 Phaseolus angularis Nutrition 0.000 claims description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 4
- 235000019484 Rapeseed oil Nutrition 0.000 claims description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 4
- 239000004473 Threonine Substances 0.000 claims description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 4
- 235000010711 Vigna angularis Nutrition 0.000 claims description 4
- 240000007098 Vigna angularis Species 0.000 claims description 4
- 229930003270 Vitamin B Natural products 0.000 claims description 4
- 229930003448 Vitamin K Natural products 0.000 claims description 4
- 229950006790 adenosine phosphate Drugs 0.000 claims description 4
- 235000004279 alanine Nutrition 0.000 claims description 4
- 239000010775 animal oil Substances 0.000 claims description 4
- 235000003704 aspartic acid Nutrition 0.000 claims description 4
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 4
- 229940118852 bifidobacterium animalis Drugs 0.000 claims description 4
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims description 4
- 229940004120 bifidobacterium infantis Drugs 0.000 claims description 4
- 229940009291 bifidobacterium longum Drugs 0.000 claims description 4
- IERHLVCPSMICTF-XVFCMESISA-N cytidine 5'-monophosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 IERHLVCPSMICTF-XVFCMESISA-N 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 235000013922 glutamic acid Nutrition 0.000 claims description 4
- 239000004220 glutamic acid Substances 0.000 claims description 4
- 239000004226 guanylic acid Substances 0.000 claims description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 4
- 235000014304 histidine Nutrition 0.000 claims description 4
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 4
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 4
- 229960000310 isoleucine Drugs 0.000 claims description 4
- 235000014705 isoleucine Nutrition 0.000 claims description 4
- 239000000905 isomalt Substances 0.000 claims description 4
- 235000010439 isomalt Nutrition 0.000 claims description 4
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 claims description 4
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 4
- 229940017800 lactobacillus casei Drugs 0.000 claims description 4
- 239000011777 magnesium Substances 0.000 claims description 4
- 229910052749 magnesium Inorganic materials 0.000 claims description 4
- 229930182817 methionine Natural products 0.000 claims description 4
- 235000008390 olive oil Nutrition 0.000 claims description 4
- 239000004006 olive oil Substances 0.000 claims description 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 4
- 239000011591 potassium Substances 0.000 claims description 4
- 229910052700 potassium Inorganic materials 0.000 claims description 4
- 235000013930 proline Nutrition 0.000 claims description 4
- 235000004400 serine Nutrition 0.000 claims description 4
- 235000008521 threonine Nutrition 0.000 claims description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 4
- 239000004474 valine Substances 0.000 claims description 4
- 235000019168 vitamin K Nutrition 0.000 claims description 4
- 239000011712 vitamin K Substances 0.000 claims description 4
- 150000003721 vitamin K derivatives Chemical class 0.000 claims description 4
- 229940046010 vitamin k Drugs 0.000 claims description 4
- 229920001202 Inulin Polymers 0.000 claims description 3
- 108091028664 Ribonucleotide Proteins 0.000 claims description 3
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 3
- 229940029339 inulin Drugs 0.000 claims description 3
- 239000002336 ribonucleotide Substances 0.000 claims description 3
- 125000002652 ribonucleotide group Chemical group 0.000 claims description 3
- 244000058871 Echinochloa crus-galli Species 0.000 claims description 2
- 235000011453 Vigna umbellata Nutrition 0.000 claims description 2
- 240000001417 Vigna umbellata Species 0.000 claims description 2
- 229960003067 cystine Drugs 0.000 claims description 2
- 229940057917 medium chain triglycerides Drugs 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 claims 1
- 244000046052 Phaseolus vulgaris Species 0.000 claims 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims 1
- 244000098338 Triticum aestivum Species 0.000 claims 1
- 235000020186 condensed milk Nutrition 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 abstract description 80
- 230000006870 function Effects 0.000 abstract description 23
- 208000036119 Frailty Diseases 0.000 abstract description 18
- 206010003549 asthenia Diseases 0.000 abstract description 18
- 241000282412 Homo Species 0.000 abstract description 9
- 230000007659 motor function Effects 0.000 abstract description 3
- 235000013305 food Nutrition 0.000 description 55
- 230000000694 effects Effects 0.000 description 28
- 210000003491 skin Anatomy 0.000 description 25
- 241001465754 Metazoa Species 0.000 description 22
- 239000000047 product Substances 0.000 description 22
- 239000003925 fat Substances 0.000 description 21
- 235000019197 fats Nutrition 0.000 description 21
- 230000004060 metabolic process Effects 0.000 description 21
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 20
- 230000003405 preventing effect Effects 0.000 description 20
- 241000699666 Mus <mouse, genus> Species 0.000 description 19
- 238000012360 testing method Methods 0.000 description 19
- 230000012010 growth Effects 0.000 description 18
- 230000001737 promoting effect Effects 0.000 description 18
- DAYLJWODMCOQEW-TURQNECASA-N NMN zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)([O-])=O)O2)O)=C1 DAYLJWODMCOQEW-TURQNECASA-N 0.000 description 17
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 17
- 230000015572 biosynthetic process Effects 0.000 description 16
- 210000004369 blood Anatomy 0.000 description 16
- 239000008280 blood Substances 0.000 description 16
- 238000011161 development Methods 0.000 description 16
- 230000018109 developmental process Effects 0.000 description 16
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 16
- 229940091258 selenium supplement Drugs 0.000 description 16
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 description 15
- 235000000346 sugar Nutrition 0.000 description 15
- 230000037396 body weight Effects 0.000 description 14
- 230000009102 absorption Effects 0.000 description 13
- 210000000988 bone and bone Anatomy 0.000 description 13
- 239000003814 drug Substances 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 12
- 230000032683 aging Effects 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 230000036541 health Effects 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 12
- 235000005911 diet Nutrition 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 230000001105 regulatory effect Effects 0.000 description 11
- 238000003786 synthesis reaction Methods 0.000 description 11
- 230000037213 diet Effects 0.000 description 10
- 244000005700 microbiome Species 0.000 description 10
- 210000003205 muscle Anatomy 0.000 description 10
- 235000015097 nutrients Nutrition 0.000 description 10
- 239000002994 raw material Substances 0.000 description 10
- 239000005862 Whey Substances 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 235000012000 cholesterol Nutrition 0.000 description 9
- 235000012631 food intake Nutrition 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 9
- 230000035790 physiological processes and functions Effects 0.000 description 9
- 235000019640 taste Nutrition 0.000 description 9
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 8
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 8
- 229960004998 acesulfame potassium Drugs 0.000 description 8
- 235000010358 acesulfame potassium Nutrition 0.000 description 8
- 239000000619 acesulfame-K Substances 0.000 description 8
- 208000007502 anemia Diseases 0.000 description 8
- 230000009286 beneficial effect Effects 0.000 description 8
- 229950006238 nadide Drugs 0.000 description 8
- 235000016709 nutrition Nutrition 0.000 description 8
- 239000011573 trace mineral Substances 0.000 description 8
- 235000013619 trace mineral Nutrition 0.000 description 8
- 235000007558 Avena sp Nutrition 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 7
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 239000002778 food additive Substances 0.000 description 7
- 210000001035 gastrointestinal tract Anatomy 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 7
- 230000003647 oxidation Effects 0.000 description 7
- 238000007254 oxidation reaction Methods 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 230000002633 protecting effect Effects 0.000 description 7
- 235000002639 sodium chloride Nutrition 0.000 description 7
- 230000014616 translation Effects 0.000 description 7
- 238000012795 verification Methods 0.000 description 7
- 230000003442 weekly effect Effects 0.000 description 7
- 201000004384 Alopecia Diseases 0.000 description 6
- 206010003210 Arteriosclerosis Diseases 0.000 description 6
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 6
- 208000011775 arteriosclerosis disease Diseases 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 6
- 150000004676 glycans Chemical class 0.000 description 6
- 210000004209 hair Anatomy 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 6
- 229920001282 polysaccharide Polymers 0.000 description 6
- 239000005017 polysaccharide Substances 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 201000004624 Dermatitis Diseases 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 241000209140 Triticum Species 0.000 description 5
- 229930003779 Vitamin B12 Natural products 0.000 description 5
- 231100000360 alopecia Toxicity 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 235000020774 essential nutrients Nutrition 0.000 description 5
- 235000013373 food additive Nutrition 0.000 description 5
- 210000003194 forelimb Anatomy 0.000 description 5
- 235000013350 formula milk Nutrition 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 235000013336 milk Nutrition 0.000 description 5
- 239000008267 milk Substances 0.000 description 5
- 210000004080 milk Anatomy 0.000 description 5
- 210000004165 myocardium Anatomy 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 238000001243 protein synthesis Methods 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 235000019163 vitamin B12 Nutrition 0.000 description 5
- 239000011715 vitamin B12 Substances 0.000 description 5
- 239000004475 Arginine Substances 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 208000001132 Osteoporosis Diseases 0.000 description 4
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N Vitamin B6 Natural products CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 4
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 210000000577 adipose tissue Anatomy 0.000 description 4
- 230000036528 appetite Effects 0.000 description 4
- 235000019789 appetite Nutrition 0.000 description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 4
- 235000009697 arginine Nutrition 0.000 description 4
- 208000010668 atopic eczema Diseases 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 235000019577 caloric intake Nutrition 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000000686 essence Substances 0.000 description 4
- 210000002468 fat body Anatomy 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 229960002989 glutamic acid Drugs 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 235000019645 odor Nutrition 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000013589 supplement Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000012549 training Methods 0.000 description 4
- 230000029663 wound healing Effects 0.000 description 4
- 206010010774 Constipation Diseases 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 244000239348 Echinochloa crus galli var. praticola Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 3
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 208000019425 cirrhosis of liver Diseases 0.000 description 3
- 239000005515 coenzyme Substances 0.000 description 3
- 210000002249 digestive system Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 210000001508 eye Anatomy 0.000 description 3
- 210000003754 fetus Anatomy 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000005021 gait Effects 0.000 description 3
- 210000001156 gastric mucosa Anatomy 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 230000037356 lipid metabolism Effects 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 239000011812 mixed powder Substances 0.000 description 3
- 239000011664 nicotinic acid Substances 0.000 description 3
- 229960003512 nicotinic acid Drugs 0.000 description 3
- 235000001968 nicotinic acid Nutrition 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 231100000572 poisoning Toxicity 0.000 description 3
- 230000000607 poisoning effect Effects 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 238000005507 spraying Methods 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 230000001502 supplementing effect Effects 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- 235000019158 vitamin B6 Nutrition 0.000 description 3
- 239000011726 vitamin B6 Substances 0.000 description 3
- 229940011671 vitamin b6 Drugs 0.000 description 3
- 230000002087 whitening effect Effects 0.000 description 3
- FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- 241000186361 Actinobacteria <class> Species 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241001107116 Castanospermum australe Species 0.000 description 2
- 208000002177 Cataract Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000193171 Clostridium butyricum Species 0.000 description 2
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 2
- 244000077995 Coix lacryma jobi Species 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 2
- 206010013774 Dry eye Diseases 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000027601 Inner ear disease Diseases 0.000 description 2
- 240000007049 Juglans regia Species 0.000 description 2
- 235000009496 Juglans regia Nutrition 0.000 description 2
- 208000000913 Kidney Calculi Diseases 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- ZFOMKMMPBOQKMC-KXUCPTDWSA-N L-pyrrolysine Chemical compound C[C@@H]1CC=N[C@H]1C(=O)NCCCC[C@H]([NH3+])C([O-])=O ZFOMKMMPBOQKMC-KXUCPTDWSA-N 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 206010029148 Nephrolithiasis Diseases 0.000 description 2
- 208000001140 Night Blindness Diseases 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 208000031845 Pernicious anaemia Diseases 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- 229920001100 Polydextrose Polymers 0.000 description 2
- 208000012287 Prolapse Diseases 0.000 description 2
- 206010039101 Rhinorrhoea Diseases 0.000 description 2
- 235000002595 Solanum tuberosum Nutrition 0.000 description 2
- 244000061456 Solanum tuberosum Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 102000004357 Transferases Human genes 0.000 description 2
- 108090000992 Transferases Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 206010046814 Uterine prolapse Diseases 0.000 description 2
- 229930003471 Vitamin B2 Natural products 0.000 description 2
- 241000589636 Xanthomonas campestris Species 0.000 description 2
- 206010048259 Zinc deficiency Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 2
- 239000003674 animal food additive Substances 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 235000021279 black bean Nutrition 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 210000004958 brain cell Anatomy 0.000 description 2
- 230000003925 brain function Effects 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000019522 cellular metabolic process Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 2
- 239000005516 coenzyme A Substances 0.000 description 2
- 229940093530 coenzyme a Drugs 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000037149 energy metabolism Effects 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 235000019688 fish Nutrition 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 235000004554 glutamine Nutrition 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 229960001518 levocarnitine Drugs 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- 230000037353 metabolic pathway Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 208000010753 nasal discharge Diseases 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000001259 polydextrose Substances 0.000 description 2
- 229940035035 polydextrose Drugs 0.000 description 2
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000186 progesterone Substances 0.000 description 2
- 229960003387 progesterone Drugs 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 2
- 235000020185 raw untreated milk Nutrition 0.000 description 2
- 235000020989 red meat Nutrition 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- 229920002477 rna polymer Polymers 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 229940055619 selenocysteine Drugs 0.000 description 2
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 description 2
- 235000016491 selenocysteine Nutrition 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 230000036559 skin health Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 235000000053 special nutrition Nutrition 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 210000001179 synovial fluid Anatomy 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- 208000027491 vestibular disease Diseases 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 235000019164 vitamin B2 Nutrition 0.000 description 2
- 239000011716 vitamin B2 Substances 0.000 description 2
- 235000020234 walnut Nutrition 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 244000226021 Anacardium occidentale Species 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102000040350 B family Human genes 0.000 description 1
- 108091072128 B family Proteins 0.000 description 1
- 235000012284 Bertholletia excelsa Nutrition 0.000 description 1
- 244000205479 Bertholletia excelsa Species 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 101800001982 Cholecystokinin Proteins 0.000 description 1
- 102100025841 Cholecystokinin Human genes 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 235000010523 Cicer arietinum Nutrition 0.000 description 1
- 244000045195 Cicer arietinum Species 0.000 description 1
- 206010009260 Cleft lip and palate Diseases 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000006069 Corneal Opacity Diseases 0.000 description 1
- 240000009226 Corylus americana Species 0.000 description 1
- 235000001543 Corylus americana Nutrition 0.000 description 1
- 235000007466 Corylus avellana Nutrition 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 244000241257 Cucumis melo Species 0.000 description 1
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 1
- 244000007835 Cyamopsis tetragonoloba Species 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 244000268590 Euryale ferox Species 0.000 description 1
- 229920002444 Exopolysaccharide Polymers 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 208000012895 Gastric disease Diseases 0.000 description 1
- 206010018275 Gingival atrophy Diseases 0.000 description 1
- 206010018276 Gingival bleeding Diseases 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 1
- 102000004195 Isomerases Human genes 0.000 description 1
- 108090000769 Isomerases Proteins 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- 208000019926 Keshan disease Diseases 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- 241000186840 Lactobacillus fermentum Species 0.000 description 1
- 241000186606 Lactobacillus gasseri Species 0.000 description 1
- 241000186604 Lactobacillus reuteri Species 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- 241000186869 Lactobacillus salivarius Species 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 235000004431 Linum usitatissimum Nutrition 0.000 description 1
- 240000006240 Linum usitatissimum Species 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 102000004317 Lyases Human genes 0.000 description 1
- 108090000856 Lyases Proteins 0.000 description 1
- 206010061274 Malocclusion Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- ABSPRNADVQNDOU-UHFFFAOYSA-N Menaquinone 1 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(C)C(=O)C2=C1 ABSPRNADVQNDOU-UHFFFAOYSA-N 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 206010035039 Piloerection Diseases 0.000 description 1
- 235000003447 Pistacia vera Nutrition 0.000 description 1
- 240000006711 Pistacia vera Species 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 235000010580 Psophocarpus tetragonolobus Nutrition 0.000 description 1
- 244000046095 Psophocarpus tetragonolobus Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 102100040756 Rhodopsin Human genes 0.000 description 1
- 108090000820 Rhodopsin Proteins 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 108010029987 Salivary Proteins and Peptides Proteins 0.000 description 1
- 102000001848 Salivary Proteins and Peptides Human genes 0.000 description 1
- 235000001498 Salvia hispanica Nutrition 0.000 description 1
- 240000005481 Salvia hispanica Species 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010046940 Vaginal prolapse Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000726445 Viroids Species 0.000 description 1
- 208000007642 Vitamin B Deficiency Diseases 0.000 description 1
- 229930003761 Vitamin B9 Natural products 0.000 description 1
- 206010047623 Vitamin C deficiency Diseases 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019730 animal feed additive Nutrition 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037237 body shape Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000007177 brain activity Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 150000001669 calcium Chemical class 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 230000001013 cariogenic effect Effects 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000003848 cartilage regeneration Effects 0.000 description 1
- 235000020226 cashew nut Nutrition 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 229940107137 cholecystokinin Drugs 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 210000004240 ciliary body Anatomy 0.000 description 1
- 208000016653 cleft lip/palate Diseases 0.000 description 1
- 210000003477 cochlea Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 231100000269 corneal opacity Toxicity 0.000 description 1
- 230000004453 corneal transparency Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000004246 corpus luteum Anatomy 0.000 description 1
- 238000005536 corrosion prevention Methods 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000000695 crystalline len Anatomy 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 235000019221 dark chocolate Nutrition 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 244000013123 dwarf bean Species 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 206010014801 endophthalmitis Diseases 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000003063 flame retardant Substances 0.000 description 1
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 1
- 235000004426 flaxseed Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000003132 food thickener Nutrition 0.000 description 1
- 210000004744 fore-foot Anatomy 0.000 description 1
- 235000013611 frozen food Nutrition 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 201000005562 gingival recession Diseases 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 150000002327 glycerophospholipids Chemical class 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 235000021331 green beans Nutrition 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 210000002478 hand joint Anatomy 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 238000003837 high-temperature calcination Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 235000006486 human diet Nutrition 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000012994 industrial processing Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 210000002011 intestinal secretion Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 210000000554 iris Anatomy 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 229960003350 isoniazid Drugs 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 230000008407 joint function Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 229940012969 lactobacillus fermentum Drugs 0.000 description 1
- 229940001882 lactobacillus reuteri Drugs 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 230000020958 lipid digestion Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 208000007106 menorrhagia Diseases 0.000 description 1
- 230000037345 metabolism of vitamins Effects 0.000 description 1
- 238000012543 microbiological analysis Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 206010028320 muscle necrosis Diseases 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 230000021688 musculoskeletal movement Effects 0.000 description 1
- 210000002346 musculoskeletal system Anatomy 0.000 description 1
- FRASJONUBLZVQX-UHFFFAOYSA-N naphthoquinone group Chemical group C1(C=CC(C2=CC=CC=C12)=O)=O FRASJONUBLZVQX-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 230000024764 neural tube development Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 210000003924 normoblast Anatomy 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000019895 oat fiber Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 239000006014 omega-3 oil Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 150000002972 pentoses Chemical class 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000036211 photosensitivity Effects 0.000 description 1
- 230000000243 photosynthetic effect Effects 0.000 description 1
- 235000019175 phylloquinone Nutrition 0.000 description 1
- 239000011772 phylloquinone Substances 0.000 description 1
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229960001898 phytomenadione Drugs 0.000 description 1
- 230000005371 pilomotor reflex Effects 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 206010035653 pneumoconiosis Diseases 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
- 230000006825 purine synthesis Effects 0.000 description 1
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 1
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 1
- 229960001327 pyridoxal phosphate Drugs 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 201000010727 rectal prolapse Diseases 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 206010038433 renal dysplasia Diseases 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 208000007442 rickets Diseases 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 208000010233 scurvy Diseases 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 235000019613 sensory perceptions of taste Nutrition 0.000 description 1
- 230000036301 sexual development Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000036548 skin texture Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 235000013322 soy milk Nutrition 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 125000005480 straight-chain fatty acid group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000037072 sun protection Effects 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 239000012209 synthetic fiber Substances 0.000 description 1
- 230000035923 taste sensation Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 206010048828 underweight Diseases 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 235000015192 vegetable juice Nutrition 0.000 description 1
- 230000001720 vestibular Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000004382 visual function Effects 0.000 description 1
- 150000003698 vitamin B derivatives Chemical class 0.000 description 1
- 235000019159 vitamin B9 Nutrition 0.000 description 1
- 239000011727 vitamin B9 Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000004552 water soluble powder Substances 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L11/00—Pulses, i.e. fruits of leguminous plants, for production of food; Products from legumes; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/13—Nucleic acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/14—Yeasts or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
- A23L7/152—Cereal germ products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/20—Malt products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Pediatric Medicine (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Microbiology (AREA)
- Agronomy & Crop Science (AREA)
- Botany (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明涉及一种增强哺乳动物抗衰老的组合物,包括:75‑90%功能组分,所述功能组分至少包括含有质量比为(2‑8):(8‑2)乳清蛋白与酪蛋白的蛋白质供能组分;5‑20%活力组分,所述活力组分选自维生素、矿物元素、益生菌、氨基酸、RNA、β‑烟酰胺单核苷酸(NMN)、DHA、硫酸软骨素中的一者或者多者;以及0‑10%辅料。本申请的增强哺乳动物抗衰老的组合物,显著提升了老年小鼠的运动机能,有效弥补老年小鼠的虚弱指数,使其各项机能均回复至2‑3月龄小鼠的水平。而小鼠的临床虚弱指数与人类一致,因此本申请具有将其用于人类,并增强人类抗衰老的前景。
Description
技术领域
本发明涉及功能保健食品领域,特别地涉及一种增强哺乳动物抗衰老的组合物。
背景技术
衰老是自然界生灵无法避免的主题。衰老可分为两类:生理性衰老和病理性衰老。无论是生理性衰老,还是病理性衰老,随着时间的推移,机体对环境的适应能力、机体本身各项机能、抵抗力都会进行性降低。衰老的主要生理表现在生理功能的减退,如肌肉骨骼运动系统变化、消化系统的变化、神经系统的变化等;和形态变化,如随着年龄的增长,体型、外形、毛发的变化等。
发生衰老的哺乳动物无论从体能、耐久力、体力方面,还是形态,均会不可避免的发生变化,而增强哺乳动物抵抗衰老,或者增强哺乳动物的运动机能是永不过时的课题。
发明内容
针对现有技术中存在的技术问题,本发明提出了一种增强哺乳动物抗衰老的组合物,包括:75-90%功能组分,所述功能组分至少包括含有质量比为(2-8): (8-2)乳清蛋白与酪蛋白的蛋白质供能组分;5-20%活力组分,所述活力组分选自维生素、矿物元素、益生菌、氨基酸、RNA、β-烟酰胺单核苷酸(NMN)、 DHA、硫酸软骨素中的一者或者多者;以及0-10%辅料。
如上所述的组合物,其中所述70%-90%的乳清蛋白由乳清蛋白由来的 WPC、乳酪蛋白由来的WPC和WPI中的一者或者多者提供,10%-30%的乳清蛋白由浓缩奶蛋白MPC、CE90GMM酪蛋白肽和酪蛋白酸盐中的一者或者多者提供。
如上所述的组合物,其中所述90%-100%的酪蛋白由浓缩奶蛋白MPC、 CE90GMM酪蛋白肽和酪蛋白酸盐中的一者或者多者提供。
如上所述的组合物,其中所述功能组分进一步包括脂质供能组分、碳水供能组分中的一者或者两者;其中,蛋白质供能组分、脂质供能组分及碳水功能组分提供的热量比为2:(2-6):(6-2);其中,所述脂质供能组分选自以下组分:植物油和/或动物油;其中,植物油选自亚麻籽油粉、中链甘油三酯MCT、菜籽油粉、葵花籽油粉、大豆卵磷脂、橄榄油粉、大米胚芽油粉中的一者或者多者;以及所述碳水供能组分选自以下组分:异麦芽酮糖、木薯糊精、异麦芽糖糊精、纤维素、半乳甘露聚糖分解产物、菊粉、抗性糊精、糊精、麦芽糊精、淀粉中的一者或者多者。
如上所述的组合物,所述功能组分包括:20%-35%蛋白质供能组分; 10%-25%脂质供能组分;以及35%-50%碳水供能组分。
如上所述的组合物,所述功能组分包括:10%-20%浓缩奶蛋白MPC80; 10%-20%WPC80乳清蛋白;1%-10%亚麻籽油;6%-16%中链甘油三酯MCT; 18%-28%异麦芽酮糖;1%-10%木薯糊精;5%-15%异麦芽糖糊精;0.1%-5%纤维素;以及0.1%-5%半乳甘露聚糖分解产物。
如上所述的组合物,其中所述益生菌选自双歧杆菌BB536、青春双歧杆菌、动物双歧杆菌、两期双歧杆菌、长双歧杆菌、短双歧杆菌、婴儿双歧杆菌、嗜酸乳杆菌、干酪乳杆菌、卷曲乳杆菌、德式乳杆菌保加利亚亚种、发酵乳杆菌、唾液乳杆菌、格氏乳杆菌、罗伊氏乳杆菌、鼠李糖乳杆菌中的一者或者多者。
如上所述的组合物,其中所述氨基酸选自牛磺酸、L-精氨酸、精氨酸、赖氨酸、组氨酸、苯丙氨酸、酪氨酸、亮氨酸、异亮氨酸、蛋氨酸、缬氨酸、丙氨酸、甘氨酸、脯氨酸、谷氨酸、丝氨酸、苏氨酸、天冬氨酸、色氨酸、胱氨酸、游离牛磺酸中的一者或者多者。
如上所述的组合物,其中所述RNA包括5-胞苷酸、5-腺苷酸、5-尿苷酸、 5-鸟苷酸组成的核糖核苷酸。
如上所述的组合物,其中所述DHA由鱼油提供。
如上所述的组合物,其中所述硫酸软骨素由鲨鱼软骨提取物提供。
如上所述的组合物,其中活力组分包括:1%-12%维生素,所述维生素选自可被生物体吸收形式的维生素A、维生素B族、维生素C、维生素D、维生素E、维生素K、卵磷脂以及在一定条件下产生维生素或促进维生素吸收的物质中的一者或多者;0.2%-8%矿物质,所述矿物质选自可被生物体吸收形式的钙、镁、钾、锌、锰、铬、铜、硒、钼、铁、碘中的一者或者多者;0.005%-0.5%益生菌;0.05%-5%氨基酸;0.002%-0.2% RNA;0.001%-3% RNA;0.001%-3% NMN;0.04%-4% DHA;以及0.04%-4%硫酸软骨素。
如上所述的组合物,其中活力组分包括:0.0001%-0.01%硫胺盐酸盐;0.0001%-0.01%核黄素;0.0002%-0.02%盐酸吡哆醇;0.0002%-0.02% VB12 水溶性;0.002%-0.2%叶酸制剂;0.0002%-0.02%含生物素酵母;0.1%-1%肌醇; 0.001%-0.1%烟酰胺;0.0005%-0.05%泛酸钙;0.008%-0.8%抗坏血酸; 0.02%-2%d-α-生育酚;0.001%-0.1%维生素A脂肪酸酯制剂;0.001%-0.1%胡萝卜素色素;0.001%-0.1%维生素D3;0.005%-0.5%维生素K2;0.06%-6%煅烧钙;0.06%-6%硫酸镁;0.06%-6%氯化钾;0.007%-0.7%含锌酵母;
0.005%-0.5%含锰酵母0.003%-0.3%含铬酵母;0.001%-0.1%含铜酵母;
0.001%-0.1%含硒酵母;0.002%-0.2%含钼酵母;0.006%-0.6%焦磷酸铁;
0.001%-0.1%含碘酵母;0.5%-10%大豆由来卵磷脂;0.04%-4%含DHA精制鱼油;0.005%-0.5%双歧杆菌BB536;0.005%-0.5%天然牛磺酸;0.04%-4%左旋肉碱;0.01%-1% L-精氨酸;0.002%-0.2% RNA;0.03%-3% NMN;0.04%-4%含有硫酸软骨素鲨鱼软骨提取物。
如上所述的组合物,所述辅料包括二氧化硅、甜味剂、酵母提取物、食用香精、瓜尔胶、黄原胶、谷物中的一者或者多者。
如上所述的组合物,所述谷物包括燕麦粉、奇亚籽粉、大麦、小豆、糯米、薏米、玉米、红豆、黑米、玄米、发芽玄米、大麦芯、胚芽大麦、麻糬玄米、麻糬小麦、麻糬黑米、毛豆、黄米、薏仁米、红糯米、糯粟、黄大豆、黑豆、稗、玉米中的一者或者多者。
如上所述的组合物,其适于糖尿病患者食用。
本申请的增强哺乳动物抗衰老的组合物,显著提升了老年小鼠的运动机能,有效弥补老年小鼠的虚弱指数,使其各项机能均回复至2-3月龄小鼠的水平。而小鼠的临床虚弱指数与人类一致,因此本申请具有将其用于人类,并增强人类抗衰老的前景。
附图说明
下面,将结合附图对本发明的优选实施方式进行进一步详细的说明,其中:
图1A是根据本申请一个实施例的不同月龄以及饲喂不同食物小鼠的食物消耗量折线图;
图1B是根据本申请一个实施例的不同月龄以及饲喂不同食物小鼠的每周能量摄入量柱状图;
图1C时根据本申请一个实施例的不同月龄以及饲喂不同食物小鼠的每周食物摄入量柱状图;
图2A是根据本申请一个实施例的不同月龄以及饲喂不同食物小鼠在试验的地1-14周的体重记录;
图2B时根据本申请一个实施例的不同月龄以及饲喂不同食物小鼠在实验开始的第12周的体重;
图3A是根据本申请一个实施例的不同月龄以及饲喂不同食物小鼠体成分分析的脂肪-体重标准化柱状图;
图3B是根据本申请一个实施例的不同月龄以及饲喂不同食物小鼠体成分分析的肌肉-体重标准化柱状图;
图4A是根据本申请一个实施例的不同月龄以及饲喂不同食物小鼠在跑步机测试中的跑步持续时间柱状图;
图4B是根据本申请一个实施例的不同月龄以及饲喂不同食物小鼠在跑步机测试中的跑步距离柱状图;
图5是根据本申请一个实施例的不同月龄以及饲喂不同食物小鼠的前肢握力大小记录柱状图;以及
图6A是根据本申请一个实施例的不同月龄以及饲喂不同食物小鼠的临床虚弱指数评估柱状图;
图6B是根据本申请一个实施例的用于临床虚弱指数评估的不同月龄以及饲喂不同食物的小鼠照片。
具体实施方式
为使本发明实施例的目的、技术方案和优点更加清楚,下面将结合本发明实施例中的附图,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
在以下的详细描述中,可以参看作为本申请一部分用来说明本申请的特定实施例的各个说明书附图。在附图中,相似的附图标记在不同图式中描述大体上类似的组件。本申请的各个特定实施例在以下进行了足够详细的描述,使得具备本领域相关知识和技术的普通技术人员能够实施本申请的技术方案。应当理解,还可以利用其它实施例或者对本申请的实施例进行结构、逻辑或者电性的改变。
本申请涉及的术语具有以下含义:
如本申请所用,术语“功能组分”是指组合物中对哺乳动物增强抗衰老起关键作用的物质,其为哺乳动物提供蛋白质、脂肪及碳水等能量。在一些实施例中,功能组分中包括蛋白质功能组分、脂质供能组分、碳水供能组分中的一者或者多者。在一些实施例中,蛋白质供能组分、脂质供能组分及碳水功能组分提供的热量比为2:(2-6):(6-2)。例如,蛋白质供能组分、脂质供能组分及碳水功能组分提供的热量比为2:2:6,或者蛋白质供能组分、脂质供能组分及碳水功能组分提供的热量比为2:3:5,或者蛋白质供能组分、脂质供能组分及碳水功能组分提供的热量比为2:4:4,或者蛋白质供能组分、脂质供能组分及碳水功能组分提供的热量比为2:5:3,或者蛋白质供能组分、脂质供能组分及碳水功能组分提供的热量比为2:6:2,或者蛋白质供能组分、脂质供能组分及碳水功能组分提供的热量比为2:2.5:5.5,或者蛋白质供能组分、脂质供能组分及碳水功能组分提供的热量比为2:3.5:4.5,或者蛋白质供能组分、脂质供能组分及碳水功能组分提供的热量比为2:4.5:3.5,或者蛋白质供能组分、脂质供能组分及碳水功能组分提供的热量比为2:5.5:2.5等。
如本申请所用,术语“蛋白质供能组分”是指可以为机体提供蛋白质的物质。蛋白质是人体的组织主要成份,也是最后的供能物质,包括WPC乳清蛋白、浓缩奶蛋白等可为机体提供蛋白质的物质。蛋白质供能组分提供的蛋白质包括但不限于乳清蛋白、酪蛋白以及各种氨基酸。如蛋白质供能组分为机体提供质量比为(2-8):(8-2)的乳清蛋白和酪蛋白,如乳清蛋白与酪蛋白质量比为 2:8,或者乳清蛋白与酪蛋白质量比为3:7,或者乳清蛋白与酪蛋白质量比为4:6,或者乳清蛋白与酪蛋白质量比为5:5,或者乳清蛋白与酪蛋白质量比为5.5:4.5,或者乳清蛋白与酪蛋白质量比为6:4,或者乳清蛋白与酪蛋白质量比为6.5:3.5,或者乳清蛋白与酪蛋白质量比为7:3,或者乳清蛋白与酪蛋白质量比为8:2。成熟的母乳中,乳清蛋白与酪蛋白比例为6:4,而该比例也是国标配方奶粉中建议的比例。本申请中,优选乳清蛋白与酪蛋白质量比为6:4,但该比例并非对本申请的限制。
乳清蛋白和酪蛋白具有不同的吸收速率,乳清蛋白被生物体吸收速度较快,分解成氨基酸的速度也较快,且含人体必须的氨基酸,可减少蛋白损失,促进蛋白合成,保护肌肉和小肠,增强免疫力,但其降解速度的也快。在一些实施例汇总,相比于酪蛋白,乳清蛋白含量更多。进一步地,在一些实施例中,需要短效蛋白和长效蛋白搭配,保持蛋白的匀速吸收,对肌肉有更好保护作用,有更持久的活力。在一些实施例中,本申请进一步包含酪蛋白。酪蛋白是一种长效蛋白,很长一段时间没保持匀速吸收,对肌肉有更好的保护作用,更持久的保持活力。在一些实施例中,提供乳清蛋白的原料可以为WPI、乳清由来的 WPC和奶酪由来的WPC中的一者或者多者。进一步地,乳清蛋白可以由 WPC80、WPC85、MPC80、MPC85WWP9010、PROGEL800、LACTOMIN80-S、 WheycoW80、WheycoW80 Instant、WheycoW80HG、WWP8010、PROGEL800 等提供。2)酪蛋白由MPC浓缩奶蛋白、CE90GMM酪蛋白肽和酪蛋白酸盐中的一者或者多者提供,例如MPC80、MPC85、MIPRODAN30(-Na)等。MPC 作为一种天然的牛乳蛋白浓缩物在营养学和功能特性上都具有优势,其主要应用之一是用于干酪加工中,提高干酪原料乳的酪蛋白含量,从而提高干酪加工的生产效率和产量。此外引起特有的营养和功能特性,可以制成各种高附加值的营养保健品及其它工业原料。
如本申请所用,术语“脂质供能组分”是指为机体提供脂肪的功能物质。脂肪是运动中最重要的能源物质,与个体的耐力有关,运动时骨骼肌摄取与利用酮体的能力提高。同时,脂肪是储存热量,维持健康,构成组织细胞所必需的基本营养物质,也是机体组织细胞的重要组成部分,同时还是从事耐力运动时的主要能源。另外,脂肪细胞还能产生一种类似激素的蛋白质,能够对入侵的病毒作出反应,所起的作用很像抗病免疫细胞。因此,拥有适量脂肪,有益于提高人体的免疫功能。脂质供能组分可以选自以下组分:植物油和/或动物油;其中,植物油选自亚麻籽油粉、中链甘油三酯MCT、菜籽油粉、葵花籽油粉、大豆卵磷脂、橄榄油粉、大米胚芽油粉中的一者或者多者。
如本申请所用,术语“碳水供能组分”是指可以为机体提供糖类或其衍生物的物质。例如,其可为机体提供果糖、麦芽糖、蔗糖、葡萄糖、纤维素以及其他物质。碳水供能组分可以选自以下组分:异麦芽酮糖、木薯糊精、异麦芽糖糊精、纤维素粉末、半乳甘露聚糖分解产物、菊粉、抗性糊精、糊精、麦芽糊精、淀粉中的一者或者多者。
如本申请所用,术语“活力组分”为机体提供必需营养成分,或者改善机体内环境的物质,如氨基酸、矿物元素、氨基酸、DHA等为机体提供必需的营养成分;益生菌、RNA、NMN和硫酸软骨素等可以改变机体的内环境,如改善机体的肠道菌群。
如本申请所用,术语“谷物”是以谷物为主要成分的物质,其可为机体提供维生素、矿物元素、纤维素、淀粉、蛋白质、脂肪、糖等以及谷物特有的营养成分。在一些实施例中,谷物可以用于改善组合物的口味。
如本申请所用,术语“辅料”是指用以提升组合物的物理性质,可以为增稠剂、增溶剂、润滑剂、防腐剂、甜味剂、谷物等食品添加剂。
如本申请所用,术语“浓缩奶蛋白MPC”是指牛乳蛋白浓缩的奶蛋白。术语“浓缩奶蛋白MPC80”是指牛乳蛋白浓缩80%纯度,蛋白质含量达到80%。其中既包含酪蛋白,又含有乳清蛋白即80%的酪蛋白,20%的乳清蛋白。乳清蛋白和酪蛋白的吸收速度不同,乳清蛋白被人体吸收速度较快,分解成氨基酸的速度也较快,但降的也快。而酪蛋白是一种长效蛋白,很长一段时间没保持匀速吸收,对肌肉有更好的保护作用,更持久的保持活力。
MPC作为一种天然的牛乳蛋白浓缩物在营养学和功能特性上都具有优势,其主要应用之一是用于干酪加工中,提高干酪原料乳的酪蛋白含量,从而提高干酪加工的生产效率和产量。此外引起特有的营养和功能特性,可以制成各种高附加值的营养保健品及其它工业原料。
如本申请所用,术语“WPC乳清蛋白”是指浓缩型乳清蛋白。术语“WPC80 乳清蛋白”中,WPC表示浓缩型乳清蛋白,80表示蛋白质含量为80%。其所含的乳清蛋白浓缩粉中含有大量必需氨基酸,是理想的食品原料。可用来增强产品的热稳定性,提高水结合力及凝胶性。可广泛应用于婴儿配方奶粉、酸奶、巧克力、巴氏杀菌和超高温灭菌产品、肉制品。
如本申请所用,术语“亚麻籽油”是指亚麻籽经工业加工后获得的包含亚麻籽油主要成分的物质。亚麻籽油对人体有降血压,减少血栓形成,预防动脉硬化和预防癌变的好处。
如本申请所用,术语“MCT”是中链甘油三酯简称MCT,是一种饱和脂肪酸,在中、低强度运动中,其分解能提供运动肌肉所需的大部分能量。
如本申请所用,术语“异麦芽酮糖”是一种低甜之甜味剂,有非常好的口感,可应用于糖果、低甜饮料及食品中。它可以单独使用或与蔗糖一起使用。它也有非常好的遮蔽异味效果。例如:对DHA的鱼油味、蔬果汁的异味和豆奶的豆腥味等都有很好的掩盖效果。同时,这种糖还能刺激肠道内有益菌群的生长和繁殖,优化人体的消化系统,具有益生元特性、适合糖尿病人使用以及对大多数细菌和酵母具有抗性
如本申请所用,术语“木薯糊精”是指从木薯中提取的一种食品淀粉。该物质通过自然酶法从木薯淀粉中获得,由于多种原因,它是一种非常珍贵的食品添加剂。麦芽糊精通常可以从一种淀粉,如大麦、小麦和马铃薯。薯麦芽糊精因其没有颜色、气味、风味或味道而广受欢迎,因此可以添加到任何食物中而不会引起味道的改变。它还具有优良的稳定性,所有这些因素使它成为食品工业中口香糖、脂肪、牛奶的替代品,以及各种稳定剂。
如本申请所用,术语“异麦芽糖糊精”也称水溶性糊精或酶法糊精。它是以各类淀粉如玉米、大米等作原料,经酶法工艺低程度控制水解转化,提纯,干燥而成的一种碳水化合物,具有甜度低,溶解性好,不易吸潮,稳定性好,难以变质的特性。该产品具有增稠性强,载体性好,发酵性小,不吸潮、无异味、易消化、低热、低甜度等特点。麦芽糊精含有大量的多糖类,另外还含有钙、铁等对人体有益的微量元素及矿物质,并能促进人体正常的物质代谢。被广泛应用于饮料、冷冻食品、糖果、麦片、奶粉、保健品等行业和医药生产中。
如本申请所用,术语“纤维素”(cellulose)是由葡萄糖组成的大分子多糖。不溶于水及一般有机溶剂。是植物细胞壁的主要成分。纤维素是自然界中分布最广、含量最多的一种多糖,占植物界碳含量的50%以上。纤维素粉末为以纤维素为主要成分的粉状物质。降解纤维素的纤维素主要存在于微生物中,一些反刍动物可以利用其消化道内的微生物消化纤维素,产生的葡萄糖供自身和微生物共同利用。虽大多数的动物(包括人)不能消化纤维素,但是含有纤维素的食物对于健康是必需的和有益的。
如本申请所用,术语“半乳甘露聚糖分解产物”是一种包含了甘露糖骨干与半乳糖旁基的多糖,有很低的热量,具有多种生理功能,可促进小肠内双歧杆菌增殖,预防便秘、结肠癌、心血管病和降血糖。可在各类食品中,按生产需要适量使用。
如本申请所用,术语“维生素”为生物必需的有机化合物,是人和动物为维持正常的生理功能而必须从食物中获得的一类微量有机物质,在人体生长、代谢、发育过程中发挥着重要的作用。维生素在体内既不参与构成人体细胞,也不为人体提供能量。维生素选自可被生物体吸收形式的维生素A、维生素B族、维生素C、维生素D、维生素E、维生素K、卵磷脂以及在一定条件下产生维生素或促进维生素吸收的物质中的一者或多者。维生素可由以下物质提供:硫胺盐酸盐、核黄素、盐酸吡哆醇、VB12、叶酸制剂、含生物素酵母、肌醇、烟酰胺、抗坏血酸、d-α-生育酚粉、维生素A脂肪酸酯制剂、胡萝卜素色素、维生素D3、维生素K2乳化粉末等。
如本文所用,术语“硫胺盐酸盐”是一种水溶性B族维生素,其磷酸盐衍生物涉及人体整体健康所需的多个细胞过程。
如本文所有,术语“核黄素”核黄素通常指的是维生素B2,还可以称它为乙种维生素2。它的主要功能如下:(1)参与体内生物氧化与能量代谢,与碳水化合物、蛋白质、核酸和脂肪的代谢有关,可提高肌体对蛋白质的利用率,促进生长发育,维护皮肤和细胞膜的完整性。具有保护皮肤毛囊粘膜及皮脂腺的功能。(2)参与细胞的生长代谢,是肌体组织代谢和修复的必须营养素,如强化肝功能、调节肾上腺素的分泌。(3)参与维生素B6和烟酸的代谢,是B族维生素协调作用的一个典范。FAD和FMN作为辅基参与色氨酸转化为尼克酸,维生素B6转化为磷酸吡哆醛的过程。(4)与机体铁的吸收、储存和动员有关。(5) 具有抗氧化活性,可能与黄素酶-谷胱甘肽还原酶有关。
如本文所用,术语“盐酸吡哆醇”盐酸吡哆醇(也叫做维生素B6或盐酸吡哆辛)与多种机体功能有关,它同时影响心理和生理健康。它是产生胃酸所需要的,并对身体的脂肪和蛋白质的吸收起辅助作用。另外,它还维系着纳/钾平衡,并促进红细胞的形成。除此之外,盐酸吡哆醇还可以防止动脉硬化,并对癌症免疫力起着重要作用。同时它还阻碍高半胱氨酸,一种已知能够影响心肌和心肌中胆固醇堆积的毒素的形成。盐酸吡哆醇还用于治疗由于异烟肼(一种治疗肺结核的药物)服用过量而引起的神经系统紊乱和贫血。
如本文所用,术语“VB12”又叫钴胺素,是唯一含金属元素的维生素。自然界中的维生素B12都是微生物合成的,高等动植物不能制造维生素B12。维生素B12是需要一种肠道分泌物(内源组分)帮助才能被吸收的惟一的一种维生素。有的人由于肠胃异常,缺乏这种内源组分,即使膳食中来源充足也会患恶性贫血。植物性食物中基本上没有维生素B12。它在肠道内停留时间长,大约需要三小时(大多数水溶性维生素只需要几秒钟)才能被吸收。维生素B12的主要生理功能是参与制造骨髓红细胞,防止恶性贫血;防止大脑神经受到破坏。
如本文所用,术语“叶酸制剂”,叶酸也叫维生素B9,是一种水溶性的维生素,由蝶啶、对氨基苯甲酸和L-谷氨酸组成,也叫蝶酰谷氨酸,是B族维生素的一种。天然的叶酸广泛存在于动植物类食品中,尤以酵母、肝及绿叶的蔬菜中含量比较多。叶酸对细胞的分裂生长及核酸、氨基酸、蛋白质的合成起着重要的作用。人体缺少叶酸,可以导致红血球的异常、未成熟细胞的增加、贫血以及白血球减少。叶酸是胎儿生长发育不可缺少的营养素,孕妇如果缺乏叶酸,可以导致胎儿出生时出现低体重、唇腭裂、心脏缺陷等。如果在怀孕头3 个月内缺乏叶酸,可以引起胎儿先天性神经管发育缺陷,导致畸形。
如本文所用,术语“含生物素酵母”中,生物素又称维生素h、辅酶r,是水溶性维生素,也属于维生素b族,b7。它是合成维生素c的必要物质,是脂肪和蛋白质正常代谢不可或缺的物质。是一种维持人体自然生长、发育和正常人体机能健康必要的营养素。它的好处如下:1、帮助脂肪、肝糖和氨基酸在人体内进行正常的合成与代谢;2、促进汗腺、神经组织、骨髓、男性性腺、皮肤及毛发的正常运作和生长,减轻湿疹、皮炎症状;3、预防白发及脱发,有助于治疗秃顶;4、缓和肌肉疼痛;5、促进尿素合成与排泄、嘌呤合成和油酸的生物合成;6、用于治疗动脉硬化、中风、脂类代谢失常、高血压、冠心病和血液循环障碍性的疾病。
如本文所用,术语“肌醇”是维生素B族中的一种,和胆碱一样是亲脂肪性的维生素;(1)降低胆固醇;促进健康毛发的生长,防止脱发;预防湿疹;帮助体内脂肪的再分配(重新分布);有镇静作用;肌醇和胆法素一起结合,制成卵黄素;肌醇在供给脑细胞营养上,扮演重要的角色。(2)有代谢脂肪和胆固醇的作用、降低胆固醇,有助预防动脉硬化;帮助清除肝脏的脂肪;促进健康毛发的生长,防止脱发、防止湿疹;缺乏肌醇会导致湿疹,头发变白等现象。
如本文所用,术语“烟酰胺”又称尼克酰胺,是烟酸的酰胺化合物。作为药物,烟酰胺既可以服用,也可以制成各种外用制剂。在化妆品领域,它的常规应用主要集中在“美白”领域,是作为美白化妆品的添加剂来使用。1、阻止黑色素沉积到角质细胞。多数人都会通过防晒等手段来避免皮肤变黑,其实只有当黑色素沉淀到角质细胞时,皮肤才会变黑。烟酰胺能够避免黑色素沉淀到角质细胞中,能有效阻挡大概40%的黑色素沉淀。2、促进有黑色素的表皮细胞的新陈代谢。烟酰胺可以为皮肤提供充足的能量,推动细胞新陈代谢,促进合成胶原质,提高细胞活动机能,促进含黑色素的细胞进行新陈代谢。3、改善肌肤合成表皮蛋白质。烟酰胺可以在皮肤表面合成表皮层蛋白质,改善皮肤质地,补充肌肤水分等。通过临床研究可以得知,含有烟酰胺的护肤品比未含烟酰胺的护肤品更能够减少人体皮肤色斑的数量和范围,长期使用含有烟酰胺的护肤品,可以促进色斑颜色淡化,改善皮肤状况。
如本文所用,术语“抗坏血酸”又叫维生素C,是一种水溶性维生素参与胶原蛋白的合成;治疗坏血病;预防牙龈萎缩、出血;预防动脉硬化;抗氧化剂;治疗贫血;防癌;保护细胞、解毒、保护肝脏;提高人体的免疫力;提高机体的应急能力。
如本文所用,术语“d-α-生育酚粉”是维生素E又名生育酚或产妊酚,在食油、水果、蔬菜及粮食中均存在。能维持生殖器官正常机能,对机体的代谢有良好的影响,能使卵巢重量啬,促进其功能,促进卵泡的成熟,使黄体增大,并可抑制孕酮在全内的氧化,从而增加孕酮的作用。此外,维生素E对月经过多、外阴瘙痒、夜间性小腿痉挛、痔疮症具有辅助治疗作用。近年来,维生素E 又被广泛用于抗衰老方面,认为它可消除脂褐素在细胞中的沉积,改善细胞的正常功能,减慢组织细胞的衰老过程。
如本文所用,术语“维生素A脂肪酸酯制剂”是不饱和的一元醇类,属脂溶性维生素。由于人体或哺乳动物缺乏维生素A时易出现干眼病,故又称为抗干眼醇。维生素A虽已能人工合成,但目前的主要来源,仍为鱼肝油制剂。本品具有促进生长,维持上皮组织如皮肤、黏膜、角膜等正常功能的作用,并参与视紫红质的合成。增强视网膜感光力,参与体内许多氧化过程,尤其是不饱和脂肪酸的氧化。如果缺乏维生素A,则生长停止、皮肤粗糙、干燥,发生干燥性眼炎及夜盲症。
如本文所用,术语“胡萝卜素色素”(carotene)是指若干种相关的不饱和烃,分子式为C40H56,由植物合成,是橘色的光合色素,为主要的维生素A源物质,主要有a、β、γ三种形式,其中最为重要的为β-胡萝卜素。食物来源主要是深色蔬菜和水果。胡萝卜素是一种最常见的维生素A补充剂。维生素A对于人体视觉发育至关重要。如果身体缺少维生素A,视力就会出现问题,甚至有夜盲症。
如本文所用,术语“维生素D3”是维生素D的一种,维生素D是一种脂溶性维生素,也被看作是一种作用于钙、磷代谢的激素前体,它与阳光有密切关系,所以又叫阳光维生素。维生素D3有一个重要的功能,就是提高人体对钙和磷的吸收。简单地说,维生素D3是帮助钙吸收的。我们都知道补钙的重要性,但是如果缺乏维生素D3,钙就不能够被很好的吸收。
如本文所用,术语“维生素K2”是一种脂溶性维生素,具有叶绿醌生物活性的萘醌基团的衍生物,是人体中不可缺少的重要维生素之一。作用:(1)治疗和预防骨质疏松症,维生素K2生成骨蛋白质,再与钙共同生成骨质,增加骨密度,防止骨折。(2)维生素K2可预防肝硬化进展为肝癌。(3)治疗维生素K2缺乏性出血症,促进凝血酶原的形成,加速凝血,维持正常的凝血时间。(4)具有利尿、强化肝脏的解毒功能,并能降低血压。
如本申请所用,术语“矿物元素”是地壳中自然存在的化合物或天然元素。又称无机盐,是人体内无机物的总称。是构成人体组织和维持正常生理功能必需的各种元素的总称,是人体必需的七大营养素之一。矿物质和维生素一样,是人体必需的元素,矿物质是无法自身产生、合成的,每天矿物质的摄取量也是基本确定的,但随年龄、性别、身体状况、环境、工作状况等因素有所不同。矿物质可以由其可吸收盐形式或者以酵母载体形式提供,进一步地,矿物质由以下物质提供:泛酸钙、煅烧钙、硫酸镁、氯化钾、含锌酵母、含锰酵母、含铬酵母、含铜酵母、含硒酵母、含钼酵母、焦磷酸铁、含碘酵母等。
如本文所用,术语“泛酸钙”主要用于医药、食品及饲料添加剂。是辅酶A 的成分,参与碳水化合物、脂肪和蛋白质的代谢作用,是人体和动物维持正常生理机能不可缺少的微量物质。泛酸钙在平时的用途范围很广泛,首先可以作为补充各项维生素,同时也能补充维生素b,其中含有丰富的蛋白质,碳水化合物,脂肪功能,维持好正常的维生素生物链的结构平衡,同时要根据个人的身体情况去使用,不能在生活中盲目的使用泛酸钙。泛酸钙易溶于水和甘油,不溶于酒精、氯仿和乙醚。用于医药、食品及饲料添加剂。是辅酶A的成分,参与碳水化合物、脂肪和蛋白质的代谢作用,临床用于治疗维生素B缺乏症,周围神经炎,手术后肠绞痛。参与蛋白质、脂肪、糖在体内的新陈代谢。
如本文所用,术语“煅烧钙”又叫活性钙,由牡蛎壳经高温煅烧、水解提纯而得的产品,主要作为营养强化剂多应用于食品中。活性钙除能补钙外还可有效去除臭味,并有保鲜、防腐的作用.由于其具有抑制微生物繁殖的功效,更是安全、广谱的抗菌剂。由于活性钙含钙高,作为补钙原料,广泛应用于各种保健品、食品等。
如本文所用,术语“硫酸镁”是一种含镁的化合物,可抑制中枢神经系统,松弛骨骼肌,具有镇静、抗痉挛以及减低颅内压等作用;硫酸镁可用作消化道造影;硫酸镁粉剂外敷可以消肿,用于治疗肢体外伤后肿胀、帮助改善粗糙的皮肤等。
如本文所用,术语“氯化钾”化学式为KCl,是一种无色细长菱形或成一立方晶体,或白色结晶小颗粒粉末,外观如同食盐,无臭、味咸。常用于低钠盐、矿物质水的添加剂。氯化钾是临床常用的电解质平衡调节药,临床疗效确切,广泛运用于临床各科。用于医药,科学应用,食品加工,食盐里面也可以以部分氯化钾取代氯化钠,以降低高血压的可能性。
如本文所用,术语“含锌酵母”中,锌是人体生理必需的微量元素之一。人体的机体含锌2—2.5克。人体内的锌主要存在于肌肉、骨骼、皮肤(包括头发) 中。
锌在人体中含量虽然不多,但是作用很关键。一是参加人体内许多金属酶的组成。锌是人机体中200多种酶的组成部分,在按功能划分的六大酶类(氧化还原酶类、转移酶类、水解酶类、裂解酶类、异构酶类和合成酶类)中,每一类中均有含锌酶。二是促进机体的生长发育和组织再生。锌是调节基因表达即调节DNA复制、转译和转录的DNA聚合酶的必需组成部分,因此,缺锌动物的突出的症状是生长、蛋白质合成、DNA和RNA代谢等发生障碍。三是促进食欲。动物和人缺锌时,出现食欲缺乏。锌可通过其参与构成的含锌蛋白对味觉和食欲发生作用,从而促进食欲。四是锌缺乏对味觉系统有不良的影响,导致味觉迟钝。因为唾液蛋白对锌的依赖性比较高。五是保护皮肤健康。动物和人都可因缺锌而影响皮肤健康,出现皮肤粗糙、干燥等现象。此外,锌还可促进伤口的愈合,增强机体抵抗力。
如本文所用,术语“含锰酵母”中,锰是人体必须的微量元素,具有促进骨骼生长发育、促进脑功能正常运行、预防贫血、调节血糖、维持脂质代谢的作用。1.促进骨骼生长发育:锰可以促进骨骼矿物质密度,参与活化硫酸软骨素合成的酶系统,促进骨骼生长发育。2.促进脑功能正常运行:锰可以防止大脑被自由基损害,锰可以与神经递质结合,改善脑的功能。3.预防贫血:锰参与人体细胞的造血功能,所以,贫血的人也有可能是缺锰。4.调节血糖:锰参与胰岛素的生产,胰岛素具有降血糖功能,所以,锰有助于调节血糖。5.维持脂质代谢:锰能够激活体内半乳糖转移酶的活性,有利于甘油三酯和胆固醇在体内的转化,维持正常的脂代谢。
如本文所用,术语“含铬酵母”中,铬是人体必不可少的一种微量元素,它能维持人体多种生理机能,主要分布于皮肤、大脑、骨骼、肌肉、肾上腺当中。铬对人体的作用有:1.能控制血糖。铬对血糖的代谢比较重要,它可以提高胰岛素的功能,使葡萄糖能够顺利进入人体的各个组织细胞,进行各种新陈代谢以及产生能量。如果患有糖尿病、低血糖,可以通过铬来调节人体当中葡萄糖的代谢。2.铬还能够保护心血管,能够有效降低胆固醇,并且预防、促进、改善动脉硬化,预防高血压等。3.铬还能控制体重,能够降低体脂含量,增加瘦肌肉组织,从而有效促进人体的各种新陈代谢,使体重维持在理想的状态。
如本文所用,术语“含铜酵母”中,铜元素对人体的作用主要包括以下几种: 1、促进血红蛋白的生成,维持人体正常血液浓度,适当的铜元素可以有效促进幼红细胞等其它红细胞的生成,帮助人体的红细胞数量处于正常范围之内,同时可保持人体的血液浓度处于正常范围之内,预防缺铁性贫血等其它贫血性疾病发生。2、铜元素可以促进人体骨质发育,铜元素属于微量元素,在人体处于婴幼儿时期,铜元素可以适当促进人体的骨骼发育,促进人体神经系统以及脑部发育,维持婴幼儿的正常生长发育,避免因为营养或者微量元素缺乏而导致婴幼儿出现佝偻病等其它疾病。3、铜元素对人体的内脏发育也有一定程度的促进作用。
如本文所用,术语“含硒酵母”中,硒具有提高人体免疫力、抗氧化等功效,可以起到预防肝硬化、保护胃黏膜、减轻化疗副作用等作用。硒是人体必需的 15大营养素之一,属于强效免疫调节剂,可以抑制病毒的繁殖能力、清除人体中的自由基,同时促进胃黏膜的修复。对于有肝病的人群适量补充硒,可以预防肝脏纤维化。有胃溃疡的人群定量服用硒,还可以促进胃黏膜防护功能稳定,使胃病症状得到缓解。化疗人群出现恶心、食欲减退、脱发等化疗副作用后,可以通过补硒减轻白细胞的下降速度,使不适症状减轻。另外,硒还具有修复胰岛细胞、保护视力等作用。但过量补硒可能会出现中毒,引起脱发、脱甲等毒副作用,所以患者需在医生的指导下补硒。
如本文所用,术语“含钼酵母”中,钼是一种化学元素,人体各个组织都含有钼,一般不会对人体造成影响及危害,若出现钼缺乏或过量的情况,则易增加诱发肾结石或中毒等几率,对健康与生活质量造成危害及影响。钼是机体不可缺少的一种元素,其是肝脏内和肠道中黄嘌呤氧化酶重要的组成成分,通常不会对人体造成影响及危害。当机体缺乏钼时,易引起生长发育迟缓或患肾结石、克山病、大骨节病等。此外,钼能维持心肌的能量代谢,对心肌有保护作用,缺钼时可造成心肌坏死。当钼过量时,则易引起中毒,对自身健康与生活质量造成危害与影响,需引起重视。除上述情况外,钼会对眼睛、皮肤等造成刺激,部分人接触钼后还可能会诱发尘肺病,出现胸痛、咳嗽、呼吸困难等症状。建议经常需要接触钼的人群, 平时做好预防措施,以免对机体造成损伤。
如本文所用,术语“焦磷酸铁”是一种无机化合物,主要用作食品添加剂、强化剂、合成纤维防火剂、防腐颜料和催化剂等。
如本文所用,术语“含碘酵母”中,碘属于人体必需的微量元素之一,既能促进物质的分解代谢,又能促进糖分、脂肪、蛋白质等营养物质的转化利用。也可促进儿童身高、体重、骨骼、肌肉的生长和性发育。还能增进食欲,保持垂体和性腺的活跃平衡。如果人体长时间缺乏碘元素,会直接影响大脑和甲状腺等部位的正常功能。但是,摄入的碘元素过量,也可能增加甲亢等疾病发生的风险。
如本申请所用,术语“益生菌”是通过定殖在人体内,改变宿主某一部位菌群组成的一类对宿主有益的活性微生物。通过调节宿主黏膜与系统免疫功能或通过调节肠道内菌群平衡,促进营养吸收保持肠道健康的作用,从而产生有利于健康作用的单微生物或组成明确的混合微生物。人体、动物体内有益的细菌或真菌主要有酵母菌、益生芽孢菌、丁酸梭菌、乳杆菌、双歧杆菌、放线菌、青春双歧杆菌、动物双歧杆菌、两期双歧杆菌、长双歧杆菌、短双歧杆菌、婴儿双歧杆菌、嗜酸乳杆菌、干酪乳杆菌、卷曲乳杆菌、德式乳杆菌保加利亚亚种、发酵乳杆菌、唾液乳杆菌、格氏乳杆菌、罗伊氏乳杆菌、鼠李糖乳杆菌等。
如本申请所用,术语“氨基酸”是人体必需的营养成分,包括8种人体或者其他脊椎动物不能自身合成,而必需从外界获取的8种氨基酸。氨基酸是基因翻译成蛋白质的必需成分。蛋白质在食物营养中的作用是显而易见的,但它在人体内并不能直接被利用,而是通过变成氨基酸小分子后被利用的。即它在人体的胃肠道内并不直接被人体所吸收,而是在胃肠道中经过多种消化酶的作用,将高分子蛋白质分解为低分子的多肽或氨基酸后,在小肠内被吸收,沿着肝门静脉进入肝脏。一部分氨基酸在肝脏内进行分解或合成蛋白质;另一部分氨基酸继续随血液分布到各个组织器官,任其选用,合成各种特异性的组织蛋白质。本申请的组合物中包含的氨基酸可以为:丙氨酸、精氨酸、天冬氨酸、半胱氨酸、谷氨酰胺、谷氨酸、组氨酸、异亮氨酸、甘氨酸、天冬酰胺、亮氨酸、赖氨酸、甲硫氨酸、苯丙氨酸、脯氨酸、丝氨酸、苏氨酸、色氨酸、酪氨酸、缬氨酸、硒半胱氨酸、吡咯赖氨酸、牛磺酸、L-精氨酸等。
如本申请所用,术语“牛磺酸”是一种由含硫氨基酸转化而来的氨基酸,应用广泛,如在中枢神经系统的功能、细胞保护作用、心肌病、肾功能不全、肾功能发育异常和视网膜神经损伤等方面都有牛磺酸。几乎所有的眼组织中都含有牛磺酸。大鼠眼组织提取物的定量分析表明,牛磺酸是视网膜、玻璃体、晶状体、角膜、虹膜和睫状体中最丰富的氨基酸。诸多研究发现,牛磺酸是调节机体正常生理活动的活性物质,具有消炎、镇痛、维持机体渗透压平衡、维持正常视觉功能、调节细胞钙平衡、降血糖、调节神经传导、参与内分泌活动、调节脂类消化与吸收、增加心脏收缩能力、提高机体免疫能力、增强细胞膜抗氧化能力、保护心肌细胞等广泛的生物学功能。
如本申请所用,术语“L-精氨酸”是蛋白质合成中的编码氨基酸,身体需要它行使多种功能。例如,它刺激人体释放特定化学品,如胰岛素和人类生长激素等。这种氨基酸还帮助清除体内的氨并有促进伤口愈合的作用。人体产生肌氨酸也需要它。在分解L-精氨酸时会产生一氧化氮,因此能扩张血管并增加血流量。正常情况下,身体本身就能生产足够的L-精氨酸。但在不足时,可以通过食用富含精氨酸的食物加以补充。L-精氨酸可以从任何含有蛋白质的食物中找到,如肉类、家禽、奶酪产品、鱼类等。而富含精氨酸的食物则包括杏仁、核桃、干向日葵仁、黑巧克力、鹰嘴豆、甜瓜、花生、生扁豆、榛子、巴西果仁、红肉类(适中)、腰果、三文鱼、开心果、黄豆及胡桃。
如本申请所用,术语“RNA”为核糖核酸(缩写为RNA,即Ribonucleic Acid),存在于生物细胞以及部分病毒、类病毒中的遗传信息载体。核糖核酸在体内的作用主要是引导蛋白质的合成。RNA有酶的活性,其与DNA和蛋白质一样重要,这种分子也被视为维持生命必需的三大分子之一。其是由5-胞苷酸、 5-腺苷酸、5-尿苷酸、5-鸟苷酸组成的核糖核苷酸。其中5-胞苷酸、5-腺苷酸、 5-尿苷酸、5-鸟苷酸都是核苷酸的一种。在RNA中用作单体。其中5-胞苷酸由核碱基胞嘧啶,戊糖核糖和磷酸基团组成。RNA在蛋白质合成的过程中起到重要作用。
如本申请所用,术语“NMN”全称:β-烟酰胺单核苷酸。是辅酶I—NAD+合成的关键中间体。NMN是人体内固有的物质,也富含在一些水果和蔬菜中。因烟酰胺属于维生素b3,因此NMN属于维生素b族衍生物范畴,其广泛参与人体多项生化反应,与免疫、代谢息息相关。NMN是烟酰胺单核苷酸 Nicotinamidemononucleotide的缩写,NMN(β-烟酰胺单核苷酸)是NAD+(辅酶Ⅰ)的直接前体物质,在人体代谢途径中合成NAD+,其功能通过NAD+体现,而NAD+即是辅酶Ⅰ,它存在于每一个细胞中参与上千种反应,也是三羧酸循环的重要辅酶,三羧酸循环是人体三大营养(糖类、脂类、蛋白质)的代谢通路,在体内提供了超过95%的能量,是人体能量枢纽。NAD+作为消耗基底能激活 SIRTUINS1-7(俗称长寿蛋白),使人体生理功能年轻化,NMN可通过调节生物钟、睡眠质量等方式改善身体机能,重返健康年轻态。
如本申请所用,术语“DHA”为二十二碳六烯酸,是人体所必需的一种多不饱和脂肪酸,在鱼油中含量较多。分子式为C22H32O2,是一种含有22个碳原子和6个双键的直链脂肪酸。动物的甘油磷脂含有不等量的DHA,在体内代谢过程中可由α-亚麻酸生成,但生成量较低,主要通过食物补充。(1)辅助脑细胞发育;(2)抗衰老作用;(3)改善血液循环;(4)降血脂等。
如本申请所用,术语“硫酸软骨素”是共价连接在蛋白质上形成蛋白聚糖的一类糖胺聚糖。在医学上主要的应用途径是作为治疗关节疾病的药品,与氨基葡萄糖配合使用,具有止痛,促进软骨再生的功效,可以从根本改善关节问题。随机安慰剂对照的临床试验已经证明,硫酸软骨素能够减少骨关节炎患者疼痛,改善关节功能、减少关节肿胀和积液防止膝关节和手关节部位的间隙狭窄。提供垫衬作用,缓和行动时的冲击和摩擦,能将水分吸入蛋白多糖分子内,使软骨变厚,并增加关节内的滑液量。软骨素的重要功能之一就是作为输送管道,把重要的氧供和营养素输送至关节,帮助清除关节内的废物,同时把二氧化碳和废物加以排除。由于关节软骨并无血液供应,因此所有的充氧、滋养及润滑作用皆来自滑液。
如本文所述,术语“大豆由来卵磷脂”又称大豆蛋黄素,是精制大豆油过程中的副产品,是通过溶剂萃取然后离心分离后通过醇洗得到。大豆卵磷脂中含有卵磷脂、脑磷脂等,具延缓衰老、预防心脑血管疾病等作用。大豆卵磷脂可增强细胞信息传递能力,从而提高大脑活力,提升细胞膜自我修复能力来保护肝脏。
如本文所述,术语“左旋肉碱”又称L-肉毒碱、维生素BT,是一种促使脂肪转化为能量的类氨基酸,红色肉类是左旋肉碱的主要来源,人体自身也可合成来满足生理需要。不是真正意义上的维生素,只是一种类似维生素的物质。具有脂肪氧化分解、减肥、抗疲劳等多方面的生理功能,作为食品添加剂广泛用于婴幼儿食品、减肥食品、运动员食品、中老年人的营养补充剂、素食主义者的营养强化剂和动物饲料添加剂等。
如本文所述,术语“二氧化硅”可以作为润滑剂,是一种优良的流动促进剂,主要作为润滑剂、抗黏剂、助流剂。特别适宜油类、浸膏类药物的制粒,制成的颗粒具有很好的流动性和可压性。还可以在直接压片中用作助流剂。作为崩解剂可大大改善颗粒流动性,提高松密度,使制得的片剂硬度增加,缩短崩解时限,提高药物溶出速度。颗粒剂制造中可作内干燥剂,以增强药物的稳定性。还可以作助滤剂、澄清剂、消泡剂以及液体制剂的助悬剂、增稠剂。
如本文所述,术语“甜味剂”可以为乙酰磺胺酸钾或者安赛蜜。安赛蜜是一种食品添加剂,化学名称为乙酰磺胺酸钾,又称AK糖,外观为白色结晶性粉末,它是一种有机合成盐,其口味与甘蔗相似。不参与机体代谢,不提供能量;甜度较高,价格便宜;无致龋齿性;对热和酸稳定性好,是当前世界上第四代合成甜味剂。
如本文所述,术语“酵母提取物”酵母是一种单细胞真菌,并非系统演化分类的单元。一种肉眼看不见的微小单细胞微生物,能将糖发酵成酒精和二氧化碳,分布于整个自然界,是一种典型的异养兼性厌氧微生物,在有氧和无氧条件下都能够存活,是一种天然发酵剂。
如本文所述,术语“瓜尔胶”又名瓜尔豆胶,是豆科植物瓜尔豆的提取物,是一种半乳甘露聚糖,一般用作食品增稠剂。
如本文所述,术语“黄原胶”又名汉生胶,是由野油菜黄单胞杆菌(Xanthomnascampestris)以碳水化合物为主要原料(如玉米淀粉)经发酵工程生产的一种作用广泛的微生物胞外多糖。它具有独特的流变性,良好的水溶性、对热及酸碱的稳定性、与多种盐类有很好的相容性,作为增稠剂、悬浮剂、乳化剂、稳定剂,可广泛应用于食品、石油、医药等20多个行业,是目前世界上生产规模最大且用途极为广泛的微生物多糖。
如本申请所用,术语“燕麦”具有以下功效:1.降低血胆固醇:水溶性纤维以及β-聚葡萄糖可以降低血中总胆固醇(Total Cholesterol)以及低密度脂蛋白胆固醇(坏的胆固醇;LDL-C)的量,以降低罹患心血管疾病的风险,并且可以增加胆酸的排泄。2.控制血糖:水溶性纤维具有平缓饭后血糖上升的效果,所以有助於糖尿病患控制血糖。3.改善便秘:因为燕麦纤维中含有β-聚葡萄糖,所以可以改善消化功能、促进肠胃蠕动,并改善便秘的情形。4.促进伤口愈合:燕麦中所含丰富的锌,可以促进伤口愈合。5.预防更年期障碍:丰富的维生素E 可以扩张末梢血管,并改善血液循环,调整身体状况,所以能减轻使更年期障碍症状。6.预防骨质疏松:要预防骨质疏松,除了增加钙的摄取外,体内也不能缺乏锰。因为燕麦中含有锰,所以也可以间接的预防骨质疏松。7.其他:还有预防贫血、控制体重等功用。
如本申请所用,术语“奇亚籽”是薄荷类植物芡欧鼠尾草(Salvia Hispanica L.)的种子,是omega-3脂肪酸含量最丰富的食物,并且含有天然抗氧化剂。奇亚籽富含的亚麻酸,是一种多不饱和脂肪酸,也是omega-3的前体物质。据研究表明,奇亚籽含有的不饱和脂肪酸占总脂肪含量的80.5%,且n-6/n-3比例合理。(人类膳食中n-6与n-3PUFA摄取比例失衡会导致心脑血管疾病、癌症、炎症以及自身免疫性疾病的发生)。
如本申请所用,术语“18种杂粮混合粉”包括大麦、黑米、玄米、发芽玄米、大麦芯、胚芽大麦、麻糬玄米、麻糬小麦、麻糬黑米、毛豆、黄米、薏仁米、红糯米、糯粟、黄大豆、黑豆、稗、玉米等谷物,其中含有蛋白质、油脂、糖类、氨基酸、维生素、矿物质等,具有谷物香气。在本申请的一些实施例中,其可用于调节组合物的口味。
本申请提供了一种增强哺乳动物抗衰老的组合物,其包括:75-90%功能组分,所述功能组分至少包括含有质量比约为(2-8):(8-2)乳清蛋白与酪蛋白的蛋白质供能组分;5-20%活力组分,所述活力组分选自维生素、矿物元素、益生菌、氨基酸、RNA、NMN、DHA、硫酸软骨素中的一者或者多者;0.01-1.5%谷物组分;以及0-10%辅料。
根据本申请的一个实施例,乳清蛋白与酪蛋白质量比为2:8,或者乳清蛋白与酪蛋白质量比为3:7,或者乳清蛋白与酪蛋白质量比为4:6,或者乳清蛋白与酪蛋白质量比为5:5,或者乳清蛋白与酪蛋白质量比为5.5:4.5,或者乳清蛋白与酪蛋白质量比为6:4,或者乳清蛋白与酪蛋白质量比为6.5:3.5,或者乳清蛋白与酪蛋白质量比为7:3,或者乳清蛋白与酪蛋白质量比为8:2。优选的,乳清蛋白与酪蛋白的质量比为(5-8):(2-5)。本申请中列举的乳清蛋白与酪蛋白的比例仅为示例,而不作为对本申请的限制。
在一些实施例中,乳清蛋白由含有乳清蛋白的物质提供,如乳清蛋白由 WPC80乳清蛋白、浓缩奶蛋白MPC80、浓缩奶蛋白MPC85等提供。在一些实施例中,70%-90%的乳清蛋白由WPC80乳清蛋白提供,10%-30%的乳清蛋白由浓缩奶蛋白MPC80提供。在一些实施例中,提供乳清蛋白的原料可以为WPI、乳清由来的WPC和奶酪由来的WPC中的一者或者多者。进一步地,乳清蛋白可以由WPC80、WPC85、MPC80、MPC85WWP9010、PROGEL800、 LACTOMIN80-S、WheycoW80、WheycoW80 Instant、WheycoW80 HG、 WWP8010、PROGEL800等提供。
在一些实施例中,酪蛋白由浓缩奶蛋白MPC80、或者浓缩奶蛋白MPC85 提供。在一些实施例中,酪蛋白由MPC浓缩奶蛋白、CE90GMM酪蛋白肽和酪蛋白酸盐中的一者或者多者提供,例如MPC80、MPC85、MIPRODAN30(-Na) 等。
在一些实施例中,功能组分进一步包括脂质供能组分、碳水供能组分中的一者或者两者;所述脂质供能组分选自植物油和/或动物油;其中,植物油选自亚麻籽油粉、中链甘油三酯MCT、菜籽油粉、葵花籽油粉、大豆卵磷脂、橄榄油粉、大米胚芽油粉中的一者或者多者;以及所述碳水供能组分选自以下组分:异麦芽酮糖、木薯糊精、异麦芽糖糊精、纤维素粉末、半乳甘露聚糖分解产物中的一者或者多者。
在一些实施例中,蛋白质供能组分、脂质供能组分及碳水功能组分提供的热量比为2:(2-6):(6-2)。例如,蛋白质供能组分、脂质供能组分及碳水功能组分提供的热量比为2:2:6,或者蛋白质供能组分、脂质供能组分及碳水功能组分提供的热量比为2:3:5,或者蛋白质供能组分、脂质供能组分及碳水功能组分提供的热量比为2:4:4,或者蛋白质供能组分、脂质供能组分及碳水功能组分提供的热量比为2:5:3,或者蛋白质供能组分、脂质供能组分及碳水功能组分提供的热量比为2:6:2,或者蛋白质供能组分、脂质供能组分及碳水功能组分提供的热量比为2:2.5:5.5,或者蛋白质供能组分、脂质供能组分及碳水功能组分提供的热量比为2:3.5:4.5,或者蛋白质供能组分、脂质供能组分及碳水功能组分提供的热量比为2:4.5:3.5,或者蛋白质供能组分、脂质供能组分及碳水功能组分提供的热量比为2:5.5:2.5等。
在一些实施例中,功能组分包括:20%-35%蛋白质供能组分;10%-25%脂质供能组分;以及35%-50%碳水供能组分。进一步地,在一些实施例中,功能组分包括:10%-20%浓缩奶蛋白MPC80;10%-20% WPC80乳清蛋白;1%-10%亚麻籽油粉;6%-16%中链甘油三酯MCT;18%-28%异麦芽酮糖;1%-10%木薯糊精;5%-15%异麦芽糖糊精;0.1%-5%纤维素粉末;以及0.1%-5%半乳甘露聚糖分解产物。
在一些实施例中,本申请的益生菌选自酵母菌、益生芽孢菌、丁酸梭菌、乳杆菌、双歧杆菌、放线菌、青春双歧杆菌、动物双歧杆菌、两期双歧杆菌、长双歧杆菌、短双歧杆菌、婴儿双歧杆菌、嗜酸乳杆菌、干酪乳杆菌、卷曲乳杆菌、德式乳杆菌保加利亚亚种、发酵乳杆菌、唾液乳杆菌、格氏乳杆菌、罗伊氏乳杆菌、鼠李糖乳杆菌等中的一者或者多者。在本申请的一些实施例中,益生菌为双歧杆菌BB536。
在本申请的一些实施例中,氨基酸选自丙氨酸、精氨酸、天冬氨酸、半胱氨酸、谷氨酰胺、谷氨酸、组氨酸、异亮氨酸、甘氨酸、天冬酰胺、亮氨酸、赖氨酸、甲硫氨酸、苯丙氨酸、脯氨酸、丝氨酸、苏氨酸、色氨酸、酪氨酸、缬氨酸、硒半胱氨酸、吡咯赖氨酸、牛磺酸、L-精氨酸中的一者或者多者。
在本申请的一些实施例中,RNA由Biochem.Corporation公司购入,名称为酵母リボ核酸(RNA)。。
在本申请的一些实施例中,18种杂粮混合粉包含大麦、黑米、玄米、发芽玄米、大麦芯、胚芽大麦、麻糬玄米、麻糬小麦、麻糬黑米、毛豆、黄米、薏仁米、红糯米、糯粟、黄大豆、黑豆、稗、玉米等谷物。
在本申请的一些实施例中,DHA由鱼油提供。在一些实施例中,硫酸软骨素由鲨鱼软骨提取物提供。
根据本申请的一个实施例,活力组分包括:1%-12%维生素,所述维生素选自可被生物体吸收形式的维生素A、维生素B族、维生素C、维生素D、维生素E、维生素K、卵磷脂以及在一定条件下产生维生素或促进维生素吸收的物质中的一者或多者;0.2%-8%矿物质,所述矿物质选自可被生物体吸收形式的钙、镁、钾、锌、锰、铬、铜、硒、钼、铁、碘中的一者或者多者;0.005%-0.5%益生菌;0.05%-5%氨基酸;0.002%-0.2% RNA;0.03%-3% RNA及NMN; 0.04%-4% DHA;以及0.04%-4%硫酸软骨素。
进一步地,在一些实施例中,活力组分包括:0.0001%-0.01%硫胺盐酸盐;0.0001%-0.01%核黄素;0.0002%-0.02%盐酸吡哆醇;0.0002%-0.02% VB12 水溶性粉末;0.002%-0.2%叶酸制剂;0.0002%-0.02%含生物素酵母;0.1%-1%肌醇;0.001%-0.1%烟酰胺;0.0005%-0.05%泛酸钙;0.008%-0.8%抗坏血酸; 0.02%-2%d-α-生育酚粉;0.001%-0.1%维生素A脂肪酸酯制剂;0.001%-0.1%胡萝卜素色素;0.001%-0.1%维生素D3;0.005%-0.5%维生素K2乳化粉末; 0.06%-6%煅烧钙;0.06%-6%硫酸镁;0.06%-6%氯化钾细粒;0.007%-0.7%含锌酵母;0.005%-0.5%含锰酵母0.003%-0.3%含铬酵母;0.001%-0.1%含铜酵母;0.001%-0.1%含硒酵母;0.002%-0.2%含钼酵母;0.006%-0.6%焦磷酸铁; 0.001%-0.1%含碘酵母;0.5%-10%大豆由来卵磷脂;0.04%-4%含DHA精制鱼油粉;0.005%-0.5%双歧杆菌BB536;0.005%-0.5%天然牛磺酸;0.04%-4%左旋肉碱;0.01%-1% L-精氨酸;0.002%-0.2% RNA;0.03%-3% NMN;0.04%-4%含有硫酸软骨素鲨鱼软骨提取物。
在一些实施例中,谷物包括燕麦粉、奇亚籽粉、大麦、小豆、燕麦、糯米、薏米、玉米、红豆、黑米、玄米、发芽玄米、大麦芯、胚芽大麦、麻糬玄米、麻糬小麦、麻糬黑米、毛豆、黄米、薏仁米、红糯米、糯粟、黄大豆、黑豆、稗、玉米中的一者或者多者。
在一些实施例中,辅料包括二氧化硅、甜味剂、酵母提取物、食用香精、瓜尔胶、黄原胶、谷物中的一者或者多者。
本申请的组合物,其GI指数为46,远低于低GI食物标准数值的55;GL 指数为5,远低于GL食物标准数值的10,适于糖尿病患者食用。
在一些实施例中,本申请的组合物具有以下组分:14.2%浓缩奶蛋白 MPC80;14.2% WPC80乳清蛋白;5.4%亚麻籽油粉;11.538%中链甘油三酯 MCT;23.29%异麦芽酮糖;4.927%木薯糊精;10.063%异麦芽糖糊精;1.049%纤维素粉末;1.25%半乳甘露聚糖分解产物。0.001%硫胺盐酸盐;0.001%核黄素;0.002%盐酸吡哆醇;0.002% VB12水溶性;0.019%叶酸制剂;0.002%含生物素酵母;0.361%肌醇;0.011%烟酰胺;0.005%泛酸钙;0.08%抗坏血酸;0.208d-α-生育酚;0.013%维生素A脂肪酸酯制剂;0.011%胡萝卜素色素;0.009%维生素D3;0.048%维生素K2乳化粉末;0.66%煅烧钙;0.623%硫酸镁;0.6%氯化钾细粒;0.078%含锌酵母;0.053%含锰酵母0.03%含铬酵母;0.012%含铜酵母;0.015%含硒酵母;0.02%含钼酵母;0.063%焦磷酸铁;0.071%含碘酵母;5.333%大豆由来卵磷脂;0.4%含DHA精制鱼油; 0.053%双歧杆菌BB536;0.049%天然牛磺酸;0.404%左旋肉碱;0.102% L- 精氨酸;0.024% RNA;0.3% NMN;0.4%含有硫酸软骨素鲨鱼软骨提取物;0.1%燕麦粉;0.1%奇亚籽粉;0.2%18种杂粮混合粉;0.5%二氧化硅;0.034%乙酰磺胺酸钾或者安赛蜜;0.16%酵母提取物;2.82%食用香精;0.08%瓜尔胶; 0.08%黄原胶。
进一步地,在一些实施例中,本申请的组合物为粉固体或者液体状态。在一些实施例中,本申请的组合物为粉状、固体压缩状,如片状、块状,或者溶解于溶剂中的液态。在一些实施例中,本申请的组合物可直接食用。在另一些实施例中,本申请的组合物可以使用水、牛奶、酸奶等液体冲服。
以下将通过实施例对本申请的技术方案加以说明。本领域技术人员应当了解,以下实施例仅为本申请的一些实施例,而不代表本申请的全部技术方案。
实施例1组合物的制备
本申请组合物的生产制备工艺流程包括:
1.收集制备该申请组合物的原料,并检测入库;
2.称量原料的重量;
3.将原料混合并制备组合物。原料的混合步骤如下:
①先把大豆由来卵磷脂、二氧化硅、左旋肉碱、酵母提取物进行手动混合;
②然后加入浓缩奶蛋白MPC80、异麦芽酮糖、亚麻籽油粉、中链甘油三酯MCT、纤维素粉末、煅烧钙、硫酸镁、氯化钾细粒、含DHA精制鱼油粉、 NMN后与①进行混合并过筛。
③加入所有维生素(d-α-生育酚粉除外)、矿物质、益生菌、牛磺酸、RNA、杂粮混合粉、燕麦、奇亚籽粉进行倍散,并进行过筛。
④最后加入WPC乳清蛋白、木薯糊精、异麦芽糊精、半乳甘露聚糖分解产物、肌醇、d-α-生育酚粉、含有硫酸软骨素鲨鱼软骨提取物、L-精氨酸、瓜尔胶、黄原胶以及香精,与③进行再次混合,即获得本申请的组合物。
在一些实施例中,获得组合物后,还可以对其进行检测、分析,或者对其包装等:
⑤检测,对堆密度、水分进行测量分析。取样递交品保进行微生物分析。
⑥原料混合结束后,进行铝袋填充→喷码→重量检测、金属探测检测、取样抽检、→装盒→喷码→重量检测、人工目视检测→装箱→喷码→装托盘并移交至自动仓进行保管等待分析结果。
本申请的组合物具有以下组分:14.2%浓缩奶蛋白MPC80;14.2% WPC80 乳清蛋白;5.4%亚麻籽油粉;11.538%中链甘油三酯MCT;23.29%异麦芽酮糖;4.927%木薯糊精;10.063%异麦芽糖糊精;1.049%纤维素粉末;1.25%半乳甘露聚糖分解产物。0.001%硫胺盐酸盐;0.001%核黄素;0.002%盐酸吡哆醇;0.002% VB12水溶性;0.019%叶酸制剂;0.002%含生物素酵母;0.361%肌醇;0.011%烟酰胺;0.005%泛酸钙;0.08%抗坏血酸;0.208d-α-生育酚; 0.013%维生素A脂肪酸酯制剂;0.011%胡萝卜素色素;0.009%维生素D3; 0.048%维生素K2乳化粉末;0.66%煅烧钙;0.623%硫酸镁;0.6%氯化钾细粒;0.078%含锌酵母;0.053%含锰酵母0.03%含铬酵母;0.012%含铜酵母; 0.015%含硒酵母;0.02%含钼酵母;0.063%焦磷酸铁;0.071%含碘酵母 5.333%大豆由来卵磷脂;0.4%含DHA精制鱼油;0.053%双歧杆菌BB536;0.049%天然牛磺酸;0.404%左旋肉碱;0.102%L-精氨酸;0.024% RNA;0.3% NMN;0.4%含有硫酸软骨素鲨鱼软骨提取物;0.1%燕麦粉;0.1%奇亚籽粉; 0.2%18种杂粮混合粉;0.5%二氧化硅;0.034%乙酰磺胺酸钾或者安赛蜜; 0.16%酵母提取物;2.82%食用香精;0.08%瓜尔胶;0.08%黄原胶。
实施例2组合物的抗衰功效验证:实验方法
在本申请中,分别选取48只小鼠,并将其分成4组,每组12只小鼠,记为A组、B组、C组和D组,每组小鼠均为同日出生、具有相同的饲喂方式和相同的生长环境。其中,A组包括10只2月龄小鼠,B组包括10只3月龄小鼠,C组和D组各包括10只12月龄小鼠。其中,A、B、C组小鼠饲喂普通鼠粮,D组小鼠饲喂的鼠粮的10%部分替换为如实施例1所示的组合物。
为使得小鼠具有良好的状态,实验开始前一周即开始监测小鼠的体重、体脂指数等参数。实验开始后,对各组小鼠饲喂其对应的食物,每周监测小鼠的粮食消耗量、能量转化量、小鼠体重、进行体成分分析、跑步机测试、握力测试、虚弱指数分析等并记录。
实施例3组合物的抗衰功效验证:食物消耗量和热量计算
在本实施例中,小鼠的分组及饲喂方式与实施例2的分组一致,此处不再赘述。
在本实施例中,食物消耗量的测量方法为:每日称重笼盖上剩余的鼠粮重量;当日鼠粮消耗量=当日添加鼠粮重量—次日剩余鼠粮重量;
在本实施例中,热量按以下换算方式计算:
普通鼠粮热量:1g≈3.5Kcal
本申请组合物热量:1g≈4.18Kcal
10%组合物替换普通鼠粮后的鼠粮理论热量:1g≈3.568Kcal
图1A是根据本申请一个实施例的不同月龄以及饲喂不同食物小鼠的食物消耗量折线图;图1B是根据本申请一个实施例的不同月龄以及饲喂不同食物小鼠的每周能量摄入量柱状图;图1C时根据本申请一个实施例的不同月龄以及饲喂不同食物小鼠的每周食物摄入量柱状图。
表1小鼠的每周食物摄入量(g/只/天)
B组 | C组 | D组 |
88.68083 | 80.38917 | 96.94750 |
90.14000 | 77.45500 | 94.40833 |
87.19667 | 79.58917 | 93.18750 |
表2小鼠的每周能量摄入量(K cal)
B组 | C组 | D组 |
310.3829 | 281.3621 | 345.9087 |
315.4900 | 271.0925 | 336.8489 |
305.1883 | 278.5621 | 332.4930 |
如图1A-1C及表1-2所示,饲喂本申请组合物的12月龄小鼠的食物摄入量、卡路里摄入量均与3月龄小鼠相当,略高于饲喂普通鼠粮的12月龄小鼠。
实施例4组合物的抗衰功效验证:体重记录
在本实施例中,每周同一时间,如每周一上午,于鼠笼中小心拿取动物,每称重完一只,便将该动物放回鼠笼中并记录体重值,直至所有动物称重结束。
表3小鼠每周体重平均值(g)
表4第12周小鼠体重平均值(g)
B组 | C组 | D组 | |
体重 | 30.47 | 34.00 | 34.45 |
图2A是根据本申请一个实施例的不同月龄以及饲喂不同食物小鼠在试验的第1-14周的体重记录;图2B时根据本申请一个实施例的不同月龄以及饲喂不同食物小鼠在实验开始的第12周的体重。表3为根据本申请一个实施例的 1-14周每周小鼠体重记录的平均值;表4为根据本申请一个实施例的第12周小鼠体重的记录平均值。如图2A-图2B及表3和表4所示,饲喂本申请组合物的12月龄小鼠的体重变化趋势与饲喂普通鼠粮的12月龄小鼠基本一致。
实施例5组合物的抗衰功效验证:EchoMRI测试
在本实施例中,所使用的仪器为供应商或制造商为EchoMRI的型号为130H 的EchoMRI仪器。实验过程为:
程序设置:选择标准轴进行仪器自检;
测试:按照EchoMRI标准操作流程进行实验。动物妥当放入测试轴内,装置仪器,自运行三次检测,得均值(更换待测动物时,清洁测试轴);
数据结果:应用Prism8.3.0软件,统计分析数据。
表5小鼠体成分分析标准化平均值(%)
B组 | C组 | D组 | |
脂肪-体重 | 11.10 | 19.76 | 21.10 |
肌肉-体重 | 85.31 | 76.56 | 76.61 |
图3A是根据本申请一个实施例的不同月龄以及饲喂不同食物小鼠体成分分析的脂肪-体重标准化柱状图;图3B是根据本申请一个实施例的不同月龄以及饲喂不同食物小鼠体成分分析的肌肉-体重标准化柱状图。表5是根据本申请一个实施例的小鼠体成分分析的脂肪-体重及肌肉-体重标准化平均值。如图3A- 图3B及表5所示,无论饲喂本申请组合物还是普通鼠粮,12月龄小鼠的脂肪- 体重比与肌肉-体重比均相当,与2月龄及3月龄小鼠显著不同。本申请组合物不改变小鼠的EchoMRI值。
实施例6组合物的抗衰功效验证:跑步机测试
本实施例中,使用的仪器为由供应商或制造商为北京智鼠多宝生物科技有限责任公司提供的型号或编号为DB030-6的动物跑步机。实验过程为:
1.程序设置:分为训练(training)/保持(maintain)/加速(accelerate)三种模式;
2.测试:
训练(Training),动物训练三天,以适应跑台及跑步这一动作;
保持(Maintain),缓慢加速至20m/min后,记录动物在该速度的力竭时间及距离;
加速(Accelerate),跑台上坡5°,每20min,速度增加5m/min,记录动物力竭时间及距离;
3.保持(maintain)/加速(accelerate)阶段,电刺激始终保持开启状态,动物持续被电10次或5s则视为力竭;其中,在本申请的一个实施例中,电刺激电流为(0.05-3)mA;进一步地,在本申请的一个实施例中,电刺激电流为 0.1mA。
4.数据结果:应用Prism8.3.0软件,统计分析数据。
表6小鼠跑步机测试
B组 | C组 | D组 | |
持续时间(s) | 1743.42 | 1685.33 | 3032.17 |
距离(cm) | 444.49 | 427.49 | 938.55 |
图4A是根据本申请一个实施例的不同月龄以及饲喂不同食物小鼠在跑步机测试中的跑步持续时间柱状图;图4B是根据本申请一个实施例的不同月龄以及饲喂不同食物小鼠在跑步机测试中的跑步距离柱状图。表6是根据本申请一个实施例的小鼠跑步机测试数据平均时。如图4A-图4B及表6所示,饲喂本申请组合物的12月龄小鼠在跑步的耐力、持续时间上均有增强,耐力及持续时间均远好于饲喂普通鼠粮的3月龄及12月龄小鼠,而与2月龄小鼠相当。
实施例7组合物的抗衰功效验证:握力测试
本实施例中,使用的仪器为由供应商或制造商为上海舜宇恒平科学仪器有限公司提供的型号或编号为MP5002型的数字握力计。实验过程为:
应用数字握力计测取动物前肢握力;
准备:只允许小鼠前爪附着在网格上,保持其躯干水平;
在开始计数前,确保小鼠抓住网格的顶部,测量时轻轻拉拽小鼠尾巴,并记录显示屏上的最大握力值。
重复此步骤两次以上,获得3个有效的前肢握力测量值。
表7小鼠握力强度测试
B组 | C组 | D组 | |
握力强度 | 104.34 | 90.66 | 106.64 |
图5是根据本申请一个实施例的不同月龄以及饲喂不同食物小鼠的前肢握力大小记录柱状图。表7是根据本申请一个实施例的小鼠握力测试结果平均值。如图5及表7所示,饲喂本申请组合物的12月龄小鼠的握力相对于饲喂普通鼠粮的12月龄小鼠有显著增强,而与2月龄和3月龄小鼠相当。
实施例8组合物的抗衰功效验证:虚弱指数评估
小鼠临床检查记录30项虚弱指数,方法参考论文《A Clinical Frailty Index inAging Mice:Comparisons with Frailty Index Data in Humans》,包括对皮肤、肌肉骨骼系统、前庭耳蜗/听觉系统、眼鼻系统、消化系统、泌尿生殖系统、呼吸系统、不适体征、体重(g)和体表温度(℃)的临床评估。
在实际的操作中,采用虚弱指数评估表根据以下特征评估A、B、C、D组小鼠的虚弱指数:威胁反射(Menace reflex)、鼻涕(Nasal discharge)、立毛 (Piloerection)、腹部膨胀(Distended abdomen)、前肢抓力(Forelimb grip strength)、前庭障碍(Vestibulardisturbance)、直肠脱垂(Rectal prolapse)、阴茎阴道/子宫脱垂(Vaginal/uterine/penile prolapse)、腹泻(Diarrhoea)、胡须缺失(Loss of whiskers)、摸骨,消瘦或过于肥胖(Body condition score)、白内障(Cataracts)、角膜透明度(Corneal opacity)、咬合不正(Malocclusions)、体温指数(SD偏差)(Temperature score)、脱毛(Alopecia)、皮毛颜色(Loss of fur colour)、皮炎(Dermatitis)、皮毛光泽(Coat condition)、肿瘤(Tumours)、驼背(Kyphosis)、尾巴坚硬(Tail stiffening)、步态障碍(Gait disorders)、震颤(Tremor)、听力缺失(Hearing loss)、眼睛分泌物/肿胀(Eye discharge/swelling)、小眼(Microphthalmia)、呼吸频率(Breathing rate/depth)、鬼脸量表(Mouse Grimace Scale)以及体重指数(SD偏差)(Body weight score) 等。
根据小鼠的自身表型,对上述特征打分,0分至1分表示该特征的由弱到强。其中,其中,0分表示缺乏该特征,0.5分表示轻微的有这个特征,1分表示明显具有该特征。将虚弱指数评分表中各项分数相加获得的总分,即为该小鼠的虚弱指数。在本实施例中,每组选取12只小鼠验证其虚弱指数,其中,B、C、 D组小鼠的虚弱指数平均值见表8。
表8小鼠虚弱指数平均值
B组 | C组 | D组 | |
虚弱指数 | 1.44 | 4.04 | 1.54 |
图6A是根据本申请一个实施例的不同月龄以及饲喂不同食物小鼠的临床虚弱指数评估柱状图;图6B是根据本申请一个实施例的用于临床虚弱指数评估的不同月龄以及饲喂不同食物的小鼠照片。表8是根据本申请一个实施例的小鼠虚弱指数记录平均值。如图6A-图6B及表8所示,饲喂申请组合物的12月龄小鼠的虚弱指数相对于饲喂普通鼠粮的12月龄小鼠有显著降低,而与3月龄小鼠相当。
在本申请中使用的仪器信息如表9所示:
表9
仪器名称 | 供应商/制造商 | 型号/编号 | |
1 | 数字握力计 | 上海舜宇恒平科学仪器有限公司 | MP5002型 |
2 | 电子天平 | 上海舜宇恒平科学仪器有限公司 | MP5002型 |
3 | 电子体温计 | 赛多利斯科学仪器(北京)有限公司 | SECURA225D-ICN |
4 | EchoMRI | EchoMRI | 130H |
5 | 动物跑步机 | 北京智鼠多宝生物科技有限责任公司 | DB030-6 |
上述实施例仅供说明本发明之用,而并非是对本发明的限制,有关技术领域的普通技术人员,在不脱离本发明范围的情况下,还可以做出各种变化和变型,因此,所有等同的技术方案也应属于本发明公开的范畴。
Claims (16)
1.一种增强哺乳动物抗衰老的组合物,包括:
75-90%功能组分,所述功能组分至少包括含有质量比为(2-8):(8-2)乳清蛋白与酪蛋白的蛋白质供能组分;
5-20%活力组分,所述活力组分选自维生素、矿物元素、益生菌、氨基酸、RNA、β-烟酰胺单核苷酸(NMN)、DHA、硫酸软骨素中的一者或者多者;以及
0-10%辅料。
2.根据权利要求1所述的组合物,其中所述70%-90%的乳清蛋白由乳清蛋白由来的WPC、乳酪蛋白由来的WPC和WPI中的一者或者多者提供,10%-30%的乳清蛋白由浓缩奶蛋白MPC、CE90GMM酪蛋白肽和酪蛋白酸盐中的一者或者多者提供。
3.根据权利要求1所述的组合物,其中所述90%-100%的酪蛋白由浓缩奶蛋白MPC、CE90GMM酪蛋白肽和酪蛋白酸盐中的一者或者多者提供。
4.根据权利要求1所述的组合物,其中所述功能组分进一步包括脂质供能组分、碳水供能组分中的一者或者两者;其中,蛋白质供能组分、脂质供能组分及碳水功能组分提供的热量比为2:(2-6):(6-2);
其中,所述脂质供能组分选自以下组分:植物油和/或动物油;其中,植物油选自亚麻籽油粉、中链甘油三酯MCT、菜籽油粉、葵花籽油粉、大豆卵磷脂、橄榄油粉、大米胚芽油粉中的一者或者多者;以及所述碳水供能组分选自以下组分:异麦芽酮糖、木薯糊精、异麦芽糖糊精、纤维素、半乳甘露聚糖分解产物、菊粉、抗性糊精、糊精、麦芽糊精、淀粉中的一者或者多者。
5.根据权利要求1所述的组合物,所述功能组分包括:
20%-35%蛋白质供能组分;
10%-25%脂质供能组分;以及
35%-50%碳水供能组分。
6.根据权利要求1所述的组合物,所述功能组分包括:
10%-20%浓缩奶蛋白MPC80;
10%-20%WPC80乳清蛋白;
1%-10%亚麻籽油;
6%-16%中链甘油三酯MCT;
18%-28%异麦芽酮糖;
1%-10%木薯糊精;
5%-15%异麦芽糖糊精;
0.1%-5%纤维素;以及
0.1%-5%半乳甘露聚糖分解产物。
7.根据权利要求1所述的组合物,其中所述益生菌选自双歧杆菌BB536、青春双歧杆菌、动物双歧杆菌、两期双歧杆菌、长双歧杆菌、短双歧杆菌、婴儿双歧杆菌、嗜酸乳杆菌、干酪乳杆菌、卷曲乳杆菌、德式乳杆菌保加利亚亚种、发酵乳杆菌、唾液乳杆菌、格氏乳杆菌、罗伊氏乳杆菌、鼠李糖乳杆菌中的一者或者多者。
8.根据权利要求1所述的组合物,其中所述氨基酸选自牛磺酸、L-精氨酸、精氨酸、赖氨酸、组氨酸、苯丙氨酸、酪氨酸、亮氨酸、异亮氨酸、蛋氨酸、缬氨酸、丙氨酸、甘氨酸、脯氨酸、谷氨酸、丝氨酸、苏氨酸、天冬氨酸、色氨酸、胱氨酸、游离牛磺酸中的一者或者多者。
9.根据权利要求1所述的组合物,其中所述RNA包括5-胞苷酸、5-腺苷酸、5-尿苷酸、5-鸟苷酸组成的核糖核苷酸。
10.根据权利要求1所述的组合物,其中所述DHA由鱼油提供。
11.根据权利要求1所述的组合物,其中所述硫酸软骨素由鲨鱼软骨提取物提供。
12.根据权利要求1所述的组合物,其中活力组分包括:
1%-12%维生素,所述维生素选自可被生物体吸收形式的维生素A、维生素B族、维生素C、维生素D、维生素E、维生素K、卵磷脂以及在一定条件下产生维生素或促进维生素吸收的物质中的一者或多者;
0.2%-8%矿物质,所述矿物质选自可被生物体吸收形式的钙、镁、钾、锌、锰、铬、铜、硒、钼、铁、碘中的一者或者多者;
0.005%-0.5%益生菌;
0.05%-5%氨基酸;
0.002%-0.2%RNA;
0.001%-3%RNA;
0.001%-3%NMN;
0.04%-4%DHA;以及
0.04%-4%硫酸软骨素。
13.根据权利要求1所述的组合物,其中活力组分包括:
0.0001%-0.01%硫胺盐酸盐;
0.0001%-0.01%核黄素;
0.0002%-0.02%盐酸吡哆醇;
0.0002%-0.02%VB12水溶性;
0.002%-0.2%叶酸制剂;
0.0002%-0.02%含生物素酵母;
0.1%-1%肌醇;
0.001%-0.1%烟酰胺;
0.0005%-0.05%泛酸钙;
0.008%-0.8%抗坏血酸;
0.02%-2%d-α-生育酚;
0.001%-0.1%维生素A脂肪酸酯制剂;
0.001%-0.1%胡萝卜素色素;
0.001%-0.1%维生素D3;
0.005%-0.5%维生素K2;
0.06%-6%煅烧钙;
0.06%-6%硫酸镁;
0.06%-6%氯化钾;
0.007%-0.7%含锌酵母;
0.005%-0.5%含锰酵母
0.003%-0.3%含铬酵母;
0.001%-0.1%含铜酵母;
0.001%-0.1%含硒酵母;
0.002%-0.2%含钼酵母;
0.006%-0.6%焦磷酸铁;
0.001%-0.1%含碘酵母;
0.5%-10%大豆由来卵磷脂;
0.04%-4%含DHA精制鱼油;
0.005%-0.5%双歧杆菌BB536;
0.005%-0.5%天然牛磺酸;
0.04%-4%左旋肉碱;
0.01%-1%L-精氨酸;
0.002%-0.2%RNA;
0.03%-3%NMN;
0.04%-4%含有硫酸软骨素鲨鱼软骨提取物。
14.根据权利要求1所述的组合物,所述辅料包括二氧化硅、甜味剂、酵母提取物、食用香精、瓜尔胶、黄原胶、谷物中的一者或者多者。
15.根据权利要求14所述的组合物,所述谷物包括燕麦粉、奇亚籽粉、大麦、小豆、糯米、薏米、玉米、红豆、黑米、玄米、发芽玄米、大麦芯、胚芽大麦、麻糬玄米、麻糬小麦、麻糬黑米、毛豆、黄米、薏仁米、红糯米、糯粟、黄大豆、黑豆、稗、玉米中的一者或者多者。
16.根据权利要求1所述的组合物,其适于糖尿病患者食用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211363795.3A CN115590204A (zh) | 2022-11-02 | 2022-11-02 | 一种增强哺乳动物抗衰老的组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211363795.3A CN115590204A (zh) | 2022-11-02 | 2022-11-02 | 一种增强哺乳动物抗衰老的组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115590204A true CN115590204A (zh) | 2023-01-13 |
Family
ID=84850886
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211363795.3A Pending CN115590204A (zh) | 2022-11-02 | 2022-11-02 | 一种增强哺乳动物抗衰老的组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115590204A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023182529A1 (ja) * | 2022-03-25 | 2023-09-28 | 万里 坂井 | 医薬組成物 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006141315A (ja) * | 2004-11-22 | 2006-06-08 | Ochi International Kk | 老化制御用栄養補助食品。 |
US20110152184A1 (en) * | 2008-07-02 | 2011-06-23 | N.V. Nutricia | Nutritional Composition for Improving Muscle Function and Daily Activity |
CN102595915A (zh) * | 2009-10-28 | 2012-07-18 | 维利奥有限公司 | 乳清蛋白产品及其制备方法 |
CN105533713A (zh) * | 2015-12-29 | 2016-05-04 | 广州市戴菊科技发展有限公司 | 一种具有抗衰老功能的医用食品及其制备方法 |
EP3085249A1 (en) * | 2015-04-24 | 2016-10-26 | Nualtra Ltd | A high protein nutritional composition |
CN107205415A (zh) * | 2014-12-26 | 2017-09-26 | 达能日尔维公司 | 包含蛋白质混合物的组合物 |
CN109452645A (zh) * | 2018-12-27 | 2019-03-12 | 山东禹王生态食业有限公司 | 一种高蛋白全营养配方粉及其制备方法 |
WO2022068137A1 (zh) * | 2020-09-29 | 2022-04-07 | 内蒙古伊利实业集团股份有限公司 | 一种乳清蛋白组合物及其制备方法和应用 |
-
2022
- 2022-11-02 CN CN202211363795.3A patent/CN115590204A/zh active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006141315A (ja) * | 2004-11-22 | 2006-06-08 | Ochi International Kk | 老化制御用栄養補助食品。 |
US20110152184A1 (en) * | 2008-07-02 | 2011-06-23 | N.V. Nutricia | Nutritional Composition for Improving Muscle Function and Daily Activity |
CN102595915A (zh) * | 2009-10-28 | 2012-07-18 | 维利奥有限公司 | 乳清蛋白产品及其制备方法 |
CN107205415A (zh) * | 2014-12-26 | 2017-09-26 | 达能日尔维公司 | 包含蛋白质混合物的组合物 |
EP3085249A1 (en) * | 2015-04-24 | 2016-10-26 | Nualtra Ltd | A high protein nutritional composition |
CN105533713A (zh) * | 2015-12-29 | 2016-05-04 | 广州市戴菊科技发展有限公司 | 一种具有抗衰老功能的医用食品及其制备方法 |
CN109452645A (zh) * | 2018-12-27 | 2019-03-12 | 山东禹王生态食业有限公司 | 一种高蛋白全营养配方粉及其制备方法 |
WO2022068137A1 (zh) * | 2020-09-29 | 2022-04-07 | 内蒙古伊利实业集团股份有限公司 | 一种乳清蛋白组合物及其制备方法和应用 |
Non-Patent Citations (1)
Title |
---|
宋志远: "科技铸就健康长寿新路", 中国高新科技, no. 22, pages 173 - 8 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023182529A1 (ja) * | 2022-03-25 | 2023-09-28 | 万里 坂井 | 医薬組成物 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102511720B (zh) | 一种水苏糖婴幼儿营养米粉和其制备方法 | |
EP2705844A1 (en) | Nutritional composition | |
CN1895067A (zh) | 减肥美容酸奶片(粉) | |
CN105815514A (zh) | 藜麦减肥奶茶 | |
CN108391811A (zh) | 一种肿瘤全营养配方食品及其应用 | |
CN103190483A (zh) | 儿童成长奶茶 | |
CN111728195B (zh) | 一种低碳、不生酮的减脂降糖代餐奶昔及其制备方法 | |
CN115251373A (zh) | 一种用于控制体重的特殊膳食食品、制备工艺及其应用 | |
CN115590204A (zh) | 一种增强哺乳动物抗衰老的组合物 | |
CN113317509B (zh) | 一种生酮营养代餐粉及其应用 | |
WO2009086614A1 (en) | Method and application of synbiotic food/feed composition for humans and animals | |
Dakia | Carob (Ceratonia siliqua L.) seeds, endosperm and germ composition, and application to health | |
CN101690591A (zh) | 牦牛骨髓多肽长骨增高片(粉) | |
CN114190441A (zh) | 一种促进儿童身高发育的配方奶粉及其制备方法 | |
EP1633377A1 (en) | A method of treating or preventing chronic wounds and a complete nutritional composition comprising glycine and/or leucine for use therein | |
CN106418067A (zh) | 一种补充体力、缓解疲劳的保健饮料 | |
CN114680339A (zh) | 一种改善肌肉衰减延缓衰老的营养补充剂及其应用 | |
CN108142936A (zh) | 一种用于肿瘤患者的海洋生物型特殊医学用途配方食品 | |
CN103330118A (zh) | 减肥药物 | |
CN106036387A (zh) | 超级藜麦儿童生长营养包 | |
CN108402462B (zh) | 一种组合物、其应用和缓解体力疲劳、增强免疫力的产品 | |
KR20190113685A (ko) | 저항전분 강화 쌀을 활용한 반려동물용 사료의 제조방법 | |
CN109845827A (zh) | 一种模拟母乳喂养儿肠道微生态的婴儿乳粉 | |
KR100734944B1 (ko) | 젖산칼슘 및 미강을 주재로 한 기능성 건강식품 조성물 | |
CN108348483A (zh) | 用于治疗或预防与组织中的超过正常数量的粒细胞相关联的疾病的可可多酚和可溶膳食纤维 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |